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Abstract
Three areas of investigation regarding a novel class of potential anti-cancer therapeutics, triple
helicate dinuclear compounds known as ‘cylinders’, have been addressed in this work - the
synthesis of a ruthenium-based cylinder, determining the cellular localisation of the cylinders,
also determining the cellular e↵ects of the cylinders.
An improved protocol for the synthesis of a ruthenium cylinder has been developed, utilising
microwave synthesis as opposed to previously used reflux techniques. Whilst not leading to
an increase in yield, the synthesis is now much shorter as there is no need for the synthesis
of intermediate compound Ru(DMSO)4Cl2, and the use of Sephadex C-25 as a solid phase for
column chromatography has led to a shorter purification protocol.
First attempts at determining the cellular localisation of the fluorescent ruthenium cylin-
der have been undertaken, with confocal microscopy showing observable fluorescence within
MDA-MB-231 breast cancer cells, but not within SKOV-3 ovarian cancer cells, suggesting some
level of preferential uptake or metabolism of cylinder between cell lines. Co-localisation exper-
iments with Hoechst nuclear stains appear to show the reduction in mean fluorescence following
treatment with iron cylinder, suggesting localisation of the cylinder within cell nuclei.
Using the I-18 beamline at Diamond Light Source, synchrotron radiation has been used to
further investigate the cellular localisation of the cylinders. A sample preparation route of
growing cells on silicon nitride windows has been developed, and allowed for the imaging of
iron and nickel cylinders within SKOV-3 cells. High levels of iron are found near the cell
membrane, corresponding to areas of high calcium concentration, whereas nickel is found more
uniformly spread throughout the cell. XANES spectra of these areas show that the iron is in an
environment closer to that of the ferric iron found in ferrihydrite as opposed to the ferrous iron
found within the cylinder.
The cellular e↵ects of cylinder treatment have also been imaged, with the main observation
being that the motility of cells is compromised by cylinder treatment. The iron cylinder causes
the production of nitric oxide within MDA-MB-231 cells. Images taken as part of control
experiments showed low levels of fluorescence within MDA-MB-231 cells, suggesting that this
cell line does produce endogenous nitric oxide, something that has been a subject of debate
within the literature.
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Chapter 1
The use and imaging of metallo-drugs
1.1 Current metallo-drugs in cancer therapy
The anti-cancer e↵ect of cisplatin was a serendipitous discovery by Barnett Rosenburg, who
was investigating the e↵ect of electric current upon the cellular division of E. coli bacteria.
The cells were kept in an aqueous ammonium chloride bu↵er and supposedly inert platinum
electrodes were used to pass a current through the solution. It was observed that the E. coli cells
changed morphology to become ling and spindle-like, instead of their normal shorter, wider
rod shape. It was initially believed that this was caused by the electrical current, but it was
then found that the platinum electrodes were in fact being hydrolysed in the bu↵er solution,
leading to the formation of various platinum compounds [19]. Rosenburg et al. then tested
a family of platinum salts on E. coli bacteria, and found that (NH4)2[PtCl6] caused an even
more pronounced elongation of the cells than had previously been observed. It was however
found that it was the Pt(IV) compound PtCl2(NH3)2 that was being generated by hydrolysis
of the electrodes, and it was this compound that was leading to the elongation of the E. coli
cells. However it was only the cis isomer of this compound, which became known as cisplatin,
that caused the cells to elongate, the trans isomer had no observable e↵ect on the cells [20].
Following subsequent animal trials on mice, cisplatin entered human trials and now, over 30
years after it was approved for clinical use, it is still routinely used in the treatment of many
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cancers, in particular testicular and ovarian cancers. Due to its success, many other platinum-
ammine compounds have been developed and tested as potential anti-cancer treatments. This
has led to another two compounds - carboplatin and oxaliplatin - entering worldwide clinical
use, with a further three compounds - nedaplatin, heptaplatin and lobaplatin - being approved
for use in individual countries [21]. Given their similarity in structure and constituent groups
(see Figure 1.1), it is unsurprising that they behave in an analogous way within a physiological
environment. The labile chloride or carboxylate ligands are replaced by water molecules to
produce mono or di-aqua species, which then bind to DNA in an irreversible way - through
metal-nitrogen bonds involving the N7 of purine DNA bases.
Figure 1.1: The structures of platinum-amine based drugs currently in clinical
use; cisplatin, carboplatin, lobaplatin (top row) and nedplatin, oxaliplatin and
heptaplatin (bottom row).
Jamieson and Lippard [22] comprehensively reviewed cisplatin-DNA interactions and con-
cluded that by far the most common DNA binding mode of cisplatin is to form 1,2-intrastrand
cross links involving adjacent guanine bases. The formation of these cross links causes struc-
tural distortions to the DNA helix, with a 45-55  ‘bending’ of the DNA towards the major groove
reported, along with an unwinding of around 79 . It has also been suggested that the binding
of cisplatin prevents transcription factors from binding to DNA, and so this halts transcription
[23]. But whilst cisplatin’s binding to DNA has been extensively investigated and appears to be
well understood, its cellular uptake and movement is still poorly explained.
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It was thought that cisplatin entered cells by a simple passive di↵usion mechanism, but more
recent work had suggested copper uptake [24] and transporter proteins [25] play a role in cis-
platin uptake. However, this hypothesis has now been dismissed although there is a correlation
between elevated levels of the human copper transporter protein (also known as hCTR1) and
cisplatin uptake [26].
Whilst the ability of the compounds shown in Figure 1.1 to bind extensively to DNA explains
their e↵ectiveness as cancer treatments, it is also the reason for their drawbacks. Their DNA
binding nature, combined with their non-selective cellular uptake, means that all cells - can-
cerous and healthy - are subjected to their actions. Whilst obviously their apoptosis-inducing
e↵ects are welcome in cancerous tissue, this can be devastating in healthy tissue and their mu-
tagenic e↵ects can actually lead to secondary cancers forming. In addition there are many un-
pleasant side e↵ects of cisplatin treatment, the most prevalent of which is nephrotoxicity - which
was known to be severe enough as to be dose limiting as far back as 1975 [27]. The source of
this toxicity is believed to be binding of platinum to sulphur containing protein residues in the
proximal tubule in the nephrons of the kidney. To combat this, ‘rescue agents’ such as sodium
diethyldithiocarbamate have been proposed to act as competitive sulphur containing binding
sites for platinum. These compounds however have their own toxic side e↵ects and so are of
limited clinical use. It is also a common observation that whilst initial patient response to cis-
platin is often positive, resistance to the drug is soon developed. Many mechanisms have been
hypothesised for this acquired resistance including changes in cellular uptake mechanism and
an increase in the rate of DNA repair.
Because of these side e↵ects, vast amounts of resources are being focused on finding a new
class of organometallic compounds which can bind to DNA in an entirely di↵erent way. As well
as investigating new modes of binding, attention has also turned to looking at di↵erent metal
centres to o↵er improved anti-cancer activity and budotitane became the first non-platinum
based metal compound to enter clinical trials in 1996 [28]. Further titanium compounds have
since been investigated [29] with compounds containing gold [30] and iron also being tested for
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anti-cancer activity. Modified versions of ferrocene showed great potential [31], however the
two other metal based compounds that have entered clinical trials both contain ruthenium.
1.2 Ruthenium-based anti-cancer drugs
The two ruthenium based compounds that have entered clinical trials - imidazolium [trans-
tetrachloro (dimethylsulfoxide)-imidazoleruthenate(III)], otherwise known as NAMI-A [32],
and indazolium [transtetrachlorobis(1H-indazole)ruthenate(III)], KP1019 [33] - both contain
a central RuCl4 moiety, nitrogen-bound heterocyclic ligands and a corresponding protonated
heterocyclic ligand counterion, and are shown in Figure 1.2. NAMI-A has recently completed
Phase I/II clinical trials as a combination treatment with gemcitabline for patients with non-
small-cell lung carcinoma. A decision on whether a new phase of clinical trials will begin will
be made soon [34].
Figure 1.2: The chemical structures of the two ruthenium compounds that have
entered clinical trials - KP1019 (left) and NAMI-A (right)
NAMI-A as suggested by its full name - New Anti-tumour Metastasis Inhibitor A - shows
poor activity in primary tumours but has a potent e↵ect on metastatic tumours. This mode of
activity is due to NAMI-A’s ability to bind to two mixed metallo-proteases, MMP2 and MMP9
[35]. Both of these enzymes have been implicated in the degradation of cellular collagen. By
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inhibiting these two enzymes the cell’s viability is not compromised, but its ability to migrate
is [36]. KP1019, which also contains a square-planar RuCl4 central moiety, shows activity in
a wide range of tumours. Ruthenium compounds attract attention due to a series of perceived
advantages over platinum based compounds including;
• The accessibility of 2+, 3+ and 4+ oxidation states in physiological conditions.
• The formation of octahedral complexes which intuitively suggests a di↵erent action to
square-planar platinum complexes.
• The ability of ruthenium compounds to behave as iron compounds do within the body
and bind to proteins including transferrin.
As these compounds are relatively new, their mode of action and their uptake is still to de defini-
tively determined. A comparison of KP1019 and its sodium analogue KP1339 show surpris-
ingly marked di↵erences in cellular uptake, localisation and toxicity [37]. KP1019 was found
to remain predominantly within cellular cytoplasm whilst KP1339 was localised within cell nu-
clei; but KP1019 was found to be more cytotoxic. This supports the hypothesis that KP1019
is primarily active in a cell’s mitochondria. Further studies on KP1019 and KP1339 support
a hypothesis that they are both taken into cells by the transferrin pathway [33]. Tumour cells
require large amounts of iron and so contain larger numbers of transferrin receptors than healthy
cells. Transferrin is capable of binding two Fe(III) ions before being transported across the cell
membrane. The concept of KP1019 binding to a protein to be transferred into cells is further
supported by results from Phase I clinical trials which state that the concentration of ruthenium
in plasma was 1000 times that found in the blood ultrafiltrate of patients, strongly suggesting
that KP1019 is found almost exclusively bound to protein within the blood stream [33]. It is
not however believed that KP1019 and NAMI-A’s activity is due to nuclear DNA binding inter-
actions. KP1019 is thought to interact primarily with mitochondria leading to depolarisation of
the mitochondrial membrane, whereas NAMI-A’s main e↵ect is to disrupt interactions between
the cell and the extracellular matrix. It has been shown to increase actin dependent cell adhesion
and reduce cell invasiveness - leading to a less active form of cancer as opposed to cell death.
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Whilst these two compounds clearly have di↵erent actions upon a cell, it is thought that both
these compounds are actually pre-cursors to actual active species. A hypothesis of ‘activation by
reduction’ has been proposed by Clarke [38] stating that the electrochemical potential of tumour
cells is lower than that of healthy cells, promoting the reduction of Ru(III) to Ru(II). This change
reduces the binding a nity of ⇡-donor ligands (such as the nitrogen-bound heterocyclic ligands
in KP1019 and NAMI-A) potentially giving the opportunity for these ligands to be substituted
by cellular proteins.
Dyson et al. have exploited electrospray mass spectrometry to help determine the cellular fate
of both KP1019 and NAMI-A, particularly in comparison to cisplatin. It was found that both
ruthenium compounds formed fewer DNA adducts than cisplatin, but it was also noted that the
adducts that were formed by KP1019 and NAMI-A were in a similar position to those formed
by cisplatin. The ruthenium compounds also showed the same strong preference for guanine
binding sites as exhibited by cisplatin and platinum based drugs oxaliplatin and carboplatin
[39]. Further work has shown that the two compounds exhibit di↵erent e↵ects upon cisplatin
resistant cells - KP1019 was more cytotoxic to these cells, but it was NAMI-A that was found
at increased levels and formed a higher number of DNA adducts when compared to its e↵ect on
cisplatin sensitive cells [40].
Whilst KP1019 and NAMI-A clearly show potential as anti-cancer compounds, they do not
appear to lead to the novel DNA binding mode that may be needed to dramatically advance
cancer therapy.
1.3 Novel DNA binding cylinders
Work within Hannon group has led to the development of supramolecular cylinders; tetraca-
tionic, triple helicate arrangements of the formula [M2L3]
4+ where M can be a variety of metals
and L is a bispyridylimine ligand with a diphenylmethane spacer. L can be easily synthesised
in good yields and when M is iron, the final cylinder structure can be synthesised in a simple
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reflux experiment without the need for further purification. The crystal structure of [Fe2L3]
4+ is
shown in Figure 1.3(a).
Figure 1.3: a) (top) - Crystal structure of [Fe2L3]
4+, with iron metal centres
shown in yellow. Hydrogen atoms, counter ions and solvent molecules are
omitted for clarity. b) (bottom) - Atomic Force Microscopy images showing the
induced coiling of DNA plasmid following treatment with [Fe2L3]
4+. Image repro-
duced with permission from Figure 3 in [1]
As the cylinders are roughly the same size as zinc fingers (around 2nm in length and 1nm
in diameter), it was hoped that these compounds would be able to bind in the major groove of
B-DNA - and they indeed do with a binding constant of greater than 107 M 1. Atomic Force
Microscopy images of calf thymus DNA (ct-DNA) following treatment with [Fe2L3]
4+ revealed
an unexpected intramolecular coiling of DNA in much the same way as DNA coils around a
histone [1]. Whilst this was a significant observation (as no other synthetic compound has been
shown to have such an e↵ect on DNA), a potentially far more exciting discovery was made
when the crystal structure of [Fe2L3]
4+ with palindromic DNA revealed that the cylinder had
crystallised at the centre of a three-way (Y-shaped) junction as shown in Figure 1.4(a).
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Figure 1.4: (a); Crystal structure of [Fe2L3]
4+-DNA complex, minor groove view.
Image reproduced with permission from Figure 2 in [2]. (b); Autoradiogram of
PAGE gel run at 25 C, showing the ability of [Fe2L3]
4+ to stabilise a DNA three-
way junction. Lanes 1-3 contain control samples of strands of DNA alone, Lanes
4-7 contain all three strands of DNA with increasing concentration of [Fe2L3]
4+
and Lane 8 contains a control sample of all three strands with 10 mM MgCl2.
Increasing cylinder concentration lead to DNA precipitation (observed in Lane
7), not increasing formation of three-way junction. Image reproduced with per-
mission from Figure 3 in [3].
This mode of binding had never been observed before, and so was further investigated using
poly acrylamide gel electrophoresis (PAGE), shown in Figure 1.4(b). This work confirmed that
this binding mode was not just an artefact of the crystallisation process, but [Fe2L3]
4+ was in
fact able to stabilise a three-way junction. The significance of this binding location is vast -
Y-shaped junctions are formed during one of a cell’s most important processes; replication. If
the cylinder can bind in a three-way junction in a cellular environment and block DNA replica-
tion, this would o↵er a possible explanation for any exhibited cytotoxic e↵ects. This new mode
of DNA binding combined with their DNA coiling ability, gives these cylinders two novel in-
teractions with DNA. As discussed earlier, novelty is a much sought after quality for DNA
binding compounds, and so an extensive study of the e↵ect of [Fe2L3]
4+ on five cell lines was
undertaken.
[Fe2L3]
4+ was shown to reduce mitochondrial activity, inhibit cell proliferation and induce
apoptosis at remarkably low concentrations - 7 µM of cylinder was enough to completely arrest
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cell growth in the SKOV-3 ovarian cancer cell line and to significantly reduce growth in HBL-
100 (breast cancer) and MRC5 (healthy lung) cell lines. The Ames and Comet assays were
used to determine the mutagenic and genotoxic-potential of the cylinder. The Ames assay
utilises bacteria which carry mutations meaning they are unable to produce histidine. These
are treated with the compound of interest and then grown in a histidine-free medium. If the
compound has mutagenic properties, the initial mutations will be reversed and allow colonies
to grow in the histidine-free medium. The Comet assay uses gel electrophoresis on lysed cells
which have been treated with the compound of interest. If the compound has a genotoxic e↵ect,
a large number of DNA strand breaks will be observed causing the formation of a comet-shaped
tail following electrophoresis. It was perhaps the most significant finding in this study that the
cylinder was able to induce cytotoxic e↵ects without exhibiting mutagenic and genotoxic e↵ects
[41].
These results combine to make these cylinders an excellent potential lead molecule for cancer
therapy - they bind to DNA in a novel mode leading to cell death, but without exhibiting some of
the toxic side e↵ects that have plagued the traditional platinum-amine drugs currently in clinical
use.
As discussed earlier, these cylinders may contain a variety of metals and a ruthenium ana-
logue ([Ru2L3]
4+) has also been synthesised [4]. Unlike KP1019 and NAMI-A, [Ru2L3]
4+ con-
tains Ru(II), not Ru(III). As it is believed KP1019 and NAMI-A are only active once reduced
to Ru(II), it was hoped that starting with a Ru(II) compound combined with the cylinder struc-
ture would give a very promising anti-cancer target compound. The crystal structure of the
ruthenium cylinder is shown in Figure 1.5.
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Figure 1.5: Crystal structure of [Ru2L3]
4+, with ruthenium metal centres shown
as large black spheres. Hydrogen atoms, counter ions and solvent molecules
are omitted for clarity. Image reproduced with permission from Figure 1 in [4].
The synthesis of the Ru cylinder is much more problematic than that of the Fe cylinder. It
requires a 5 day reflux reaction and a time consuming purification process. However, cytotoxic
studies on this compound show that the more di cult synthetic procedure is worth pursuing.
[Ru2L3]
4+ has been shown to possess IC50 values for HBL-100 and T47D breast cancer cell
lines which are only 2-5 times lower than that of cisplatin [4]. However, of equal interest was
the finding that [Ru2L3]
4+ is inactive against SKOV-3 cells when just 7uM of [Fe2L3]
4+ has
been shown to completely arrest their proliferation [42]. This gives the first indication that the
SKOV-3 cells are showing selective uptake of the cylinders based on their metal centres. If
there is any way that these cylinders could be tailored so that they are selectively taken up by
one cell type over another, and in particular di↵erentiating between healthy and cancerous cells,
this would clearly represent a major breakthrough in the design of cancer therapies.
[Ru2L3]
4+ has also been shown to have the ability, unlike [Fe2L3]
4+, to induce single-strand
breaks in DNA following irradiation with visible or UV light, mainly at guanine bases due to the
production of singlet oxygen [43]. This opens up the possibility of investigating the ruthenium
cylinder as a potential photodynamic therapy agent. [Ru2L3]
4+ has also been shown to prevent
the binding of the taq-polymerase enzyme to DNA, suggesting that the cylinders can e↵ectively
block DNA replication by sitting at the replication fork [44].
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The cytotoxic potential of these supramolecular cylinders is clear but work in this area must
now concentrate on determining their cellular uptake mechanism and localisation to determine
if the DNA binding observed in solution is replicated in a cellular environment. The first work
aimed at determining the cellular localisation used Inductively Coupled Plasma Mass Spec-
trometry (ICP-MS) [42]. HL-60 blood cells treated with ruthenium cylinder were lysed and
centrifuged to separate into nuclei and cell cytosol. A control experiment using cisplatin was
also prepared. As ruthenium and platinum are not naturally found within human cells, all traces
of these metals found within cells must be attributable to [Ru2L3]
4+ or cisplatin. Using ICP-MS
it was found that over 80% of the available ruthenium was taken into the cells and nearly 85%
of the ruthenium found within cells was found in the nuclei. This compares favourably with
ciplatin where just a third of the platinum found within cells was found with the nuclei. This
result suggested two things, firstly that the ruthenium cylinder localises within the nucleus and
that it may be actively transported into the cell.
However it cannot be said for certain that the ruthenium enters the nucleus (or indeed the
cell) as intact cylinder. Therefore there is a need to supplement assay and DNA solution studies
by tracking the cylinder’s fate within a cellular environment.
1.4 The cellular imaging of metallo-drugs
1.4.1 The advantages of imaging drugs in vivo
Whilst there are many assays that can be performed to try and determine the action of any com-
pound upon a cell, each assay may only allow for one particular enzyme or cell organelle to
be studied. For example, the Ames test will determine if any mutagenic e↵ects are produced,
the Comet assay will show the level of DNA damage caused and an MTT assay can be used to
determine the viability of cells, by measuring a cell’s ability to metabolise the yellow MTT salt
to a purple formazan. Using this approach means that it di cult to appreciate all the e↵ects a
compound may have upon a cell. However, there are a wide variety of imaging techniques that
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can be utilised that allows the user to look at multiple e↵ects at once - for example, phase con-
trast microscopy can be used to observe a compound’s e↵ects on cell morphology and motility.
There are also multiple applications for fluorescence microscopy - structures within a cell can
be fluorescently labelled to gain information about the compound’s e↵ects on those structures,
or if the compound has fluorescent properties its cellular localisation can be determined. Imag-
ing also has the potential to improve the screening of potential drug candidates by allowing the
in vitro investigation of e↵ects which are currently being studied in vivo at a great financial
and time cost - a prominent example of this is the micronucleus assay. This assay detects cells
that have su↵ered chromosomal damage which leads to some chromosomes being unable to
separate e↵ectively during the anaphase segment of cell division. Traditionally the assay has
been performed by examining the bone marrow of mice which have been treated with a drug
candidate compound [45]. This scale of testing requires grams of the compound and it will
be performed relatively late in the clinical trial process as, in line with ICH M3(R2) (which is
followed by the European Medicinal Agency and US FDA) this in vivo genotoxicity testing is
not required before the first human trial [46]. However, by staining the nuclei of a population
of cells in vitro as shown in Figure 1.6, the formation of any micronuclei can by observed using
milligrams of compound, and as an in vitro test, can be performed early on during compound
screening, potentially as a complement to other genotoxic tests such as the Comet assay [5].
Figure 1.6: Cultured cells with nuclei stained with fluorescent dye - control sam-
ple (left) showing healthy nuclei and treated sample (right) showing the presence
of micronuclei, highlighted in yellow circles. Image reproduced with permission
from Figure 3 in [5].
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Cellular uptake can also be studied by a variety of techniques, such as ICP-MS as discussed
earlier. Barton et al. have employed a variety of techniques to determine the uptake mechanism
of a series of ruthenium compounds [47][6], which are shown in Figure 1.7. Several techniques
such as temperature controlled experiments, metabolic inhibition, transporter inhibition and
membrane potential modulation all followed by analysis by flow cytometry were employed to
determine the mechanism of cellular uptake. After testing several inhibitors, it was concluded
that the compound entered by passive di↵usion.
Figure 1.7: Structures of ruthenium compounds investigated by Barton et al.,
image reprinted with permission from [6].Copyright 2007 American Chemical
Society.
Whilst these experiments are of course perfectly valid and give a reliable conclusion, if the
samples had been imaged instead of being analysed by flow cytometry there was the potential
to obtain a huge amount of extra information. Information such as; did any of the inhibitors
used actually lead to a delayed uptake of the compound, or did the modulation of the membrane
potential lead to localisation of the compound in a di↵erent cell organelle than before?
As reviewed in detail by Watson et al. [48], there a variety of compounds that can be used to
label transporter proteins or the endosomes formed during endocytotic uptake of compounds.
Therefore simple co-localisation experiments can be performed to determine the uptake mech-
anism of the compound. In particular, events at the cell membrane can be studied in great detail
using the technique of Total Internal Reflection (TIRF) microscopy.
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A traditional argument against the use of imaging is the throughput rate of samples - it can
be argued that the imaging of compounds within cells may be so slow it negates any benefits
obtained from analysing compounds in this way. However the development of commercial
systems to allow for the high throughput of multi-well plates has dramatically increased the
number of samples that can be analysed within a given time frame [49], and so provides the
possibility for imaging techniques to be a real option for investigating potential drug candidates.
1.4.2 The cellular imaging of currently used metallo-compounds
There have been attempts to image the cellular localisation of cisplatin by the addition of a
fluorophore [50] [7] [8], or by the formation of fluorescent nanoparticles with an outer coating
of cisplatin [51]. Some images taken from [7] and [8] are shown in Figure 1.8. These papers all
reported observable fluorescence of their cisplatin based compounds. The fluorophore-tagged
cisplatin compounds used in [50], [7] and [8] were also between them studied for co-localisation
with lysosomes and Golgi bodies showing again how the imaging of compounds within cells
can be used to gather information quickly that may not be easily obtainable from assays.
Figure 1.8: Left - ovarian cancer cell treated with fluorscein tagged cisplatin
(green), and then stained with Alexa Fluor 647 phalloidin (red) to identify actin,
and Hoechst 33342 to stain the nucleus. Image reproduced with permission
from Figure 2 in [7]. Right - Ovarian cancer cell treated with an anthracene
tagged cisplatin, shown in blue and stained with LysoTracker Red to determine
localisation of lysosomes. The overlay of these images is shown in bottom right.
Images reproduced with permission from Figure 5 in [8]. Both examples suggest
the fluorophore-tagged cisplatin is localised in vesicles as opposed to being
spread throughout the cytoplasm.
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The addition of a fluorphore to a potential drug candidate is a useful technique for imaging
its localisation but this now represents an ‘unknown variable’ as the compound being imaged is
not the same compound that would be used clinically. If however the compound of interest pos-
sesses an inherent fluorescence, cellular imaging can add another dimension of understanding
to its cellular uptake and localisation.
1.4.3 The cellular imaging of ruthenium-based compounds
As discussed in detail in Section 2.2, the cylinder with the most potential to be used as part of
fluorescence imaging studies is the ruthenium cylinder. The is due to the d6 ruthenium centres
found within this compound - combinations of d6 metals with high field ligands such as 2,2’-
bipyridine or 1,10-phenanthroline lead to compounds with large Stokes shifts and good quantum
yields. There are many reported examples of d6 transition metal complexes being investigated
as fluorescent probes, but this discussion will focus on ruthenium compounds. The most widely
studied ruthenium compound is [Ru(bpy)3]
2+.
[Ru(bpy)3]
2+ has unusual photophysical properties which make it an attractive compound
to study. The absorption spectrum shows an MLCT centred at 450nm, and excitation at this
wavelength leads to a triplet excited state. So relaxation and interconversion back to the singlet
ground state configuration is slow, giving [Ru(bpy)3]
2+ an unusually long fluorescence lifetime
in the order of 1µs [52]. [Ru(bpy)3]
2+ also has an exceptionally high fluorescence yield of over
0.9 [53]. The combination of these two properties has lead to attention focusing on other Ru-N6
chromophores in the hope of finding other compounds with attractive photophysical properties.
There are two possible uses for fluorescent ruthenium compounds; either as imaging probes
or to track the cellular localisation of potential cytotoxic compounds. The use of ruthenium
compounds as DNA probes has been investigated since the first discovery of so called ‘light
switch’ compounds. These compounds, again predominantly containing d6 octahedral metal
ions undergo an MLCT upon excitation only when they are bound to DNA. The first compound
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shown to behave in this way was [Ru(bpy)2(dppz)]
2+ [54]. The source of this fluorescence is
unclear, but the intercalation of [Ru(bpy)2(dppz)]
2+ allows for overlap between the phenazine
rings and the DNA bases o↵ering an alternative decay mechanism to the protonation of the
phenazine seen when [Ru(bpy)2(dppz)]
2+ is excited in aqueous solution.
Thomas et al. have used a dinuclear ruthenium compound to selectively label breast cancer
cells [9]. Their compound contains two Ru(phen)2 moieties linked by a tetrapyridophenazine
group - [(phen)2Ru(tpphz)Ru(phen)2]
4+. This compound is non-emissive in water, but emits
at 660nm following binding to DNA [55]. High magnification imaging of cells treated with
this compound has produced images of individual chromosomes, and lambda stacking experi-
ments during live cell imaging have shown that this compound can actually distinguish between
duplex and non-duplex DNA. Excitingly, Thomas et al. have also discovered they can target mi-
tochondrial DNA by changing the delivery mechanism of [(phen)2Ru(tpphz)Ru(phen)2]
4+ [10].
By encapsulating the compound in a polymer vesicle that is only broken down within the acidic
endosomes, the ruthenium compound is released into the cytoplasm, and then preferentially lo-
cates within mitochondria. This raises interesting questions about why the compound should
localise within the mitochondrial DNA as opposed to nuclear DNA, and suggests that when
treated with free, unencapsulated compound cells actively transport it into the cell and then into
the nucleus.
Figure 1.9 shows a collection of images of [(phen)2Ru(tpphz)Ru(phen)2]
4+ localised to both
nuclear and mitochondrial DNA.
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Figure 1.9: a) The structure of [(phen)2Ru(tpphz)Ru(phen)2]
4+. b) Flu-
orescence confocal microscopy images of [(phen)2Ru(tpphz)Ru(phen)2]
4+ in
MCF-7 breast cancer cells (red), nuclear DNA stain DAPI (blue) and over-
lay of two images showing co localisation of the two following treatment
with [(phen)2Ru(tpphz)Ru(phen)2]
4+ in media solution. c) High magnifi-
cation of mitotic cells showing individual chromosomes. d) Images of
[(phen)2Ru(tpphz)Ru(phen)2]
4+ in MCF-7 breast cancer cells (red), mitochon-
drial DNA stain Mitotracker Red (blue) and over lay of two images, showing co-
localisation of the two following treatment with [(phen)2Ru(tpphz)Ru(phen)2]
4+
encapsulated in polymer vesicles. Images (a-c) reproduced with permission
from Figure 4 in [9], image (d) reproduced with permission from Figure 2 in [10].
As well as using using luminescent compounds and investigating their DNA binding proper-
ties, a strategy of attaching a luminescent ruthenium moiety to compounds which are already
known to bind to cellular targets. This approach has been exploited by Turro et al. who linked
an Ru-N6 centre to an ethidium moiety which is known to intercalate between DNA bases [11].
The resulting compound known as RuEth, shown in Figure 1.10 was spectroscopically shown
to increase in fluorescence intensity when bound to RNA, and when breast cancer cells were
incubated with RuEth, areas of high fluorescence intensity were observed in the cell nucleolus
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where ribosomal RNA is synthesised.
Figure 1.10: a) Brightfield image and b) Fluorescence confocal microscopy im-
ages of MCF-7 cells treated with RuEth showing localisation of RuEth within the
nucleolus. c) Structure of RuEth. Images (a-c) reproduced with permission fro
Figure 5 from [11].
Following on from work developing [Ru(bpy)2(dppz)]
2+ DNA ‘light switch’, the Barton
group have produced a series on papers detailing the imaging of ruthenium compounds
within cells. A library of ruthenium dipyridophenazine (dppz) complexes were prepared with
[Ru(dip)2(dppz)]
2+ (where dip = diphenyl phenanthroline) shown to significantly increase lu-
minescence of HeLa cells treated with the compound, as shown by flow cytometry [6]. Cellular
imaging of this compound shows fluorescence located predominantly within the cytoplasm.
This work was taken forward by the synthesis of RuRrRk - a ruthenium compound with phen,
dppz and a modified bpy ligand. The bipyridine ligand links the ruthenium centre to a 4-peptide
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long conjugate, RrRK (R = L-arginine, r =D-arginine and K = L-lysine). Flow cytometry again
showed that the compound behaves in a ‘light switch’ manner, and when incubated with HeLa
cells areas of fluorescence within the cell nucleus were observed [12]. Structures of the com-
pounds used by Barton et al. and images of them within HeLa cells are shown in Figure 1.11.
Figure 1.11: a) Structure of [Ru(dip)2(dppz)]
2+, where N-N is diphenyl phenan-
throline. b) Fluorescence confocal microscopy images of HeLa cells treated
with [Ru(dip)2(dppz)]
2+ showing fluorescence spread throughout the cytoplasm.
c) Structure of RuRrRK. d) Image of HeLa cells treated with RuRrRK, with flu-
orescence now observed within the cell nucleus. Images (a-b) reproduced with
permission from Figure 3 in [6], images (c-d) reproduced with permission from
Figure 2 in [12].
Very recent work from Lin et al. has profiled three ruthenium based compounds for their
cytotoxic activity and used fluorescence confocal microscopy to confirm that all of these
compounds localise with the nucleus of liver cancer cells [56]. As discussed in Section 1.4.1,
the Barton group have investigated the uptake mechanism of their compounds, but it is only
from imaging studies that the full cellular localisation of the compounds have been determined.
37
Ruthenium compounds show great potential as anti-cancer drugs, due to their entirely di↵er-
ent interactions within cells when compared to traditional platinum drugs. Ru-N6 compounds
also have a variety of applications as imaging probes and so combining a potential drug can-
didate with the advantages of being imaged within cells represents a great opportunity to fully
explore its cellular action.
1.5 The aims of this work
This work therefore had two aims;
• The primary aim of this work was to use imaging techniques to attempt to determine
the cellular localisation of our supramolecular cylinders to determine if the DNA binding
properties of the cylinders shown in solution are replicated in a cellular environment.
Several fluorescence microscopy techniques were planned such as live cell imaging to
track fluorescent compounds, as well as co-localisation studies with cellular dyes.
• The secondary aim was to also image the e↵ects these compounds have on a variety of
cell lines, initially to look at and investigate any changes in morphology and motility.
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Chapter 2
The synthesis and spectroscopic properties
of novel DNA binding fluorescent cylinders
2.1 Previously synthesised cylinders
As discussed in Section 1.3, the cylinders can be synthesised to contain a variety of metal
centres. However, not all of these cylinders are suitable for imaging studies due to their spec-
troscopic properties. The absorption spectra of cylinders containing iron and zinc are shown
in Figure 2.1. These spectra reveal that the Zn cylinder has no excitable transitions within the
visible range of light. Whilst there are absorption bands within the UV region, exciting at these
wavelengths is not suitable during the live cell imaging that is required to complete the aims of
this work.
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Figure 2.1: Absorption spectra of Fe and Zn cylinders in the range of 220-
800 nm, both spectra have been normalised to one at the point of maximum
absorption to allow for comparability. The spectra show that the Fe cylinder has
its maximum absorption at 572nm, caused by a metal to ligand charge transfer,
whilst the Zn cylinder has no observable absorption within the visible range,
making it unsuitable for cellular imaging studies.
The absorption spectrum of Fe cylinder shows a metal-ligand charge transfer (MLCT) with
a maximum at 572nm. For the purpose of imaging studies, it is the MLCT transition which
would ideally be used to determine the localisation of the compound, as this confirms that the
cylinder structure is still intact. The closest commercially available laser line is the 568nm
line, produced either by a krypton/argon gas laser or by a solid state sapphire laser. Unfortu-
nately neither of these were readily available, so it was not considered possible to pursue the
fluorescence imaging studies of [Fe2L3]
4+. As well as the attractive toxicology properties of
ruthenium compounds, it was decided that using the ruthenium cylinder o↵ered the best op-
portunity to complete cell fluorescence imaging studies, and so work began on improving the
synthetic protocol of [Ru2L3]
4+.
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2.2 Improving synthetic protocols for Ru cylinder
The synthesis of [Ru2L3]
4+ was first published in 2007, and briefly comprises a 5-day reflux
of Ru(DMSO)4Cl2 and ligand in ethylene glycol at 200 C under a nitrogen atmosphere [4].
An extensive purification protocol of alumina column chromatography was utilised to obtain
pure compound, however the reported yield was just 0.3%, with the main impurities being
polymeric or double stranded species. Whilst work within the group has led to a more e↵ective
purification protocol using silica column chromatography [57], the initial synthesis stage is
still time consuming, and often leads to such large excesses of by-products that the amount of
compound that can be isolated is so small it cannot be fully characterised, meaning it is often
better to start again. Due to the broad peaks observed in the 1H NMR spectrum and m/z values
seen in ESI-MS spectra of crude reaction product, it is believed that the major product is a d5 low
spin Ru(III) double stranded cylinder. This suggests that once the double stranded compound
or polymer side products are formed, the reflux conditions aren’t strong enough to force the
reaction to completion and form the triple stranded cylinder which led to a search for a more
e cient synthesis, as presented below. It is noted at this point that as the published protocol does
not always lead to a successful outcome, all synthetic attempts using non-published protocols
were repeated on several occasions before determining if the new protocol was worth pursuing.
The first strategy considered for improving Ru cylinder synthesis was to consider the start-
ing materials used. The synthetic route for the synthesis of the ligand is well established and
1H NMR analysis of all ligand batches synthesised showed no unassigned peaks. It was there-
fore determined that this synthetic route could not be improved upon. Attention was therefore
turned to the other starting material, [Ru(DMSO)4Cl2]. The synthesis of cis-[Ru(DMSO)4Cl2]
was first described in [58], and involves refluxing RuCl3 · 3H2O in a molar excess of DMSO.
As the final compound contains no protons suitable for 1H NMR analysis, characterisation of
the compound relies on ESI-MS or crystallography studies. A literature review for the syn-
thesis of [Ru(DMSO)4Cl2] revealed that the only deviation from Evans’ originally published
route were variations in the length of time spent refluxing the materials, but this did not lead
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to a significant increase in reported yields. It was however noted that some authors included a
step to recrystallise crude [Ru(DMSO)4Cl2] from DMSO solvent [59]. This was therefore per-
formed by dissolving crude [Ru(DMSO)4Cl2] in the minimum volume of hot DMSO solvent to
give a deep red solution, anticipating that yellow [Ru(DMSO)4Cl2] would form upon allowing
the solution to cool to room temperature. Initial attempts led to no crystallisation being ob-
served, and so the [Ru(DMSO)4Cl2] was re-precipitated using acetone and then isolated using
filtration and allowed to dry in vacuo. However the isolated product was orange in colour and
so this was discarded as it was clear that the product was contaminated with other ruthenium
species. Following attempts concentrated on encouraging crystallisation, regardless of the size
of crystals obtained. Therefore syntheses were performed whereby the solution was immedi-
ately either refrigerated at 5 C, or immersed in an ice bath. Whilst crystals were duly observed
under both of these conditions, the high boiling point of DMSO (189 C) means that DMSO
does not evaporate under atmospheric conditions. Even under a vacuum, it was not possible to
remove all the DMSO solvent and so the resulting crystals were filtered and then allowed to dry
in vacuo. As with the crude material, the crystals were characterised using ESI-MS and were
confirmed to contain [Ru(DMSO)4Cl2], but as ESI-MS is a qualitative and not quantitative tech-
nique, it cannot be determined if the re-crystallisation process had increased the purity of the
final [Ru(DMSO)4Cl2]. The recrystallised [Ru(DMSO)4Cl2] was then used in attempted syn-
theses of Ru cylinder using the published protocol, but all syntheses resulted in the formation of
a dark red solution; a tell tale sign that the predominant reaction product was double stranded
cylinder. From these results, it was shown that the recrystallisation of [Ru(DMSO)4Cl2] did not
lead to a more e↵ective synthetic route and so this was not pursued further.
It was perhaps to be expected that refinement of the synthesis of the cylinder starting materials
would not lead to a significant improvement of cylinder yield - the starting material contains
ruthenium in a d6 low spin configuration and so is classically inert, meaning large amounts of
energy are needed to cause the Ru(DMSO)4Cl2 to react. Experience within the lab led to the
observation that the synthesis of [Ru2L3]
4+ often gave higher yields if the oil bath used in the
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reflux synthesis was pre-heated to 200 C before the reaction vessel was immersed, instead of
starting the reaction at room temperature. The apparent need for immediate high energy meant
that utilising microwave synthesis seemed a logical route to investigate. Traditional heating
methods, such as the oil bath, led to a temperature gradient developing within the reaction
vessel as the heat is transferred from the oil to the vessel, then from the vessel to the solvent
and reagents. Using microwave energy instead causes dielectric heating to take place, which
gives rapid, uniform heating throughout the entire vessel. The heating is rapid if appropriate
microwave transparent glassware is used delivering the energy directly to the reagents, and
uniform if the cavity containing the vessel is designed so that the radiation reflects from the
walls of the cavity to the vessel used. No contact between the vessel and the energy source
is required [60]. There are several examples of microwave chemistry being used to synthesise
novel ruthenium compounds, or to improve the yield or reaction time required of previously
synthesised compounds [61, 62, 63], and in 2008 Glasson et al. described the synthesis of a
ruthenium triple helicate using microwave irradiation; with a reported yield of 36% [64]. It was
therefore hoped that the use of microwave energy along with an improved purification process
would lead to a greatly improved yield.
All microwave work was performed using a Discovery System machine (CEM, USA), which
uses sealed vessels with a recommended total volume of 20 ml. This meant that all aspects
of the reaction needed to be considered both to design a successful synthetic protocol and to
prevent damage to the instrument. Solvents interact with microwaves based on their polarity
- non-polar solvents such as toluene and hexane are transparent to microwaves and so a polar
solvent must be used. As discussed earlier, the Ru cylinder synthesis requires a large amount
of energy to the activation barrier, and so a high reaction temperature was required. Whilst
one advantage of using microwave synthesis is that it can allow a solvent to reach a higher
temperature than it would do under reflux conditions, the microwave requires a closed reaction
system so further consideration was given to the vapour pressure that would be generated by
each solvent at a temperature of 200 C. The microwave used can operate up to a maximum
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pressure of 435 psi, so any solvent with a vapour pressure above this at 200 C was immediately
ruled out for investigation. Using the Antoine equation as shown below, and parameters as
taken from [65] and [66], the vapour pressures of available solvents at 200 C were calculated
as included in the Table 2.1.
lnP = A -
B
T +C
Table 2.1: Table showing the Antoine parameters for six selected solvents, and
their calculated expected vapour pressure. Note that for DMSO, the parameters
quoted require temperature (denoted as T in Equation above) to be given in
degrees Kelvin, and so is taken as 473K. For all other solvents, temperature is
given in degrees Celsius.
Solvent A B C Expected
Vapour Pressure
at 200 C / psi
Water 16.3872 3885.70 230.170 226.7
Methanol 16.5785 3638.27 239.500 583.8
Ethanol 16.8958 3795.17 230.918 472.4
Acetonitrile 14.8950 3413.10 250.523 218.8
DMSO 15.8617 4717.40 41.5900 117.2
Ethylene Glycol 15.7567 4187.46 178.650 15.9
This analysis showed that common solvents such methanol and ethanol were unsuitable for
use in this protocol, but it also revealed that the estimated vapour pressure of DMSO is 117.2
psi at 200 C. Whilst this is within the acceptable range to use within the microwave, it is known
that DMSO decomposes under microwave irradiation into gaseous species [67], which can lead
to pressure building up within the system. This meant that the favoured starting material -
Ru(DMSO)4Cl2 - was no longer suitable to be used in this synthesis. RuCl3 · xH2O was there-
fore used, in a 2:3 ratio with ligand and heated to 225 C in ethylene glycol for 4 hours, following
Glasson et al.’s procedure. This however led to a large pressure build up within the system and
the reaction could not be safely controlled under these conditions. With Glasson et al.’s proce-
dure used as a starting point, work was performed to develop a suitable protocol for Ru cylinder
synthesis.
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For each set of conditions tested as part of this work, the crude reaction mixture was worked
up in line with published protocol [4] by adding it to a saturated aqueous solution of NH4PF6,
and then re-precipitating from acetonitrile using diethyl ether. This crude material was then sub-
jected to 1H NMR and ESI-MS analysis to determine if the material contained any [Ru2L3]
4+;
if no cylinder was identified at this stage the sample was discarded and a fresh synthesis was
prepared. [Ru2L3]Cl4 is easily characterisable using mass spectrometry due to the unique iso-
tope pattern of ruthenium, with seven stable isotopes observable. The full characterisation of
[Ru2L3]Cl4 is given in section 6.3.2. To prevent instrument damage, further syntheses per-
formed on the microwave were set to limit pressure to 70 psi (4.8 bar), as this is well below the
expected vapour pressure for ethylene glycol at 200 C and also well within the recommended
guidelines for using this instrument. Should this pressure limit be reached, the microwave will
stop heating the reaction until the pressure has decreased below this limit. As initial attempts
were focused on determining if Ru cylinder was formed under the selected temperature and
pressure conditions, only small quantities of starting materials were used with the aim of scal-
ing up quantities once suitable conditions had been found. Therefore 0.4 mmol of RuCl3 · xH2O
and 0.6 mmol of ligand were combined in 20 ml of ethylene glycol and heated to 180 C, using
260W for 4 hours. It was noted that the pressure within the reaction vial increased to 70 psi, at
which point the temperature of the system was 170 C. This showed that these conditions were
either generating a gaseous species, or the solvent was contaminated with another solvent with
a higher vapour pressure at 180 C, most likely water. This reaction gave a dark red solution,
which was shown subjected to the work up as described above but no Ru cylinder related peaks
were obvious within the 1H NMR spectrum, so this sample was discarded. These conditions
were repeated with the same results achieved, and so the conditions were altered to increase the
temperature to 200 C, and the maximum allowable pressure within the system was increased to
80 psi. Initially these conditions led to the same results as seen previously with the temperature
achieved within the reaction vial again limited by the build up of pressure within the system, but
when repeated, these conditions led to a dark brown solution which a↵orded a red/brown solid
when worked up as described previously. 1H NMR and ESI-MS analysis showed that this crude
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mixture contained Ru cylinder and so this sample was purified using silica gel chromatography.
[Ru2L3]
4+ was isolated in its pure form following three successive silica gel columns, eluted
as the first orange band using a 3:1 mixture of acetonitrile and deionised water containing a
final concentration of 10 mM NH4PF6. This gave a final yield of 1 mg, which represents a
0.25% yield with respect to starting materials. Although conditions had now been found that
lead to the formation of Ru cylinder, the achieved yield was below that previously published
and so the protocol was adapted to incorporate a stage where the glassware and ethylene glycol
were purged with N2 before beginning the reaction, as would be done if performing the reaction
under reflux conditions.
The glassware used in the microwave is specially designed for the instrument and so does not
connect to standard laboratory equipment such as a Schlenk line. This meant the only way to
purge the glassware was to use an inverted funnel to create a curtain of N2 under which the vial
containing the solid reagents was kept. The ethylene glycol was purged in a Schlenk flask and
then transferred to the vial underneath the curtain, before the lid was placed on the vial. The
vial was then subjected to the same conditions as before, heated at 198 C for 4 hours, and this
gave an orange/brown solution which was also precipitated using saturated aqueous NH4PF6,
and then re-precipitated from acetonitrile using diethyl ether. The same purification routine as
described above was followed and this gave a final yield of 3 mg (0.9%). Whilst this is still
a small mass of final product, this protocol gives a higher yield to that of the published reflux
protocol and it has been achieved with a vastly reduced reaction time, achieving the aim of
creating a more e cient synthetic protocol. Attempts were made to scale up this protocol by
doubling the amount of [RuCl3 · xH2O] and ligand used, but this lead only to crude material
where only polymeric or double stranded cylinder were visible in 1H NMR analysis.
It was consistently noted that the syntheses which led to the formation of Ru cylinder were
those where the pressure within the microwave vial remained close to 0 psi. This suggests that
it is contamination of the reaction mixture with another solvent with a higher vapour pressure at
these temperatures that is preventing the reaction from going to completion. It cannot be said if
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this observation is purely an artefact of having set an arbitrary limit on the pressure within the
system, or if this is an observation that can be applied to failed syntheses that have been observed
whilst performing the reaction under reflux conditions. As the reflux conditions require that the
reaction is performed in apparatus that has been purged with N2, it too is performed in a closed
system meaning that any water contamination of the solvent will remain in the system for the
entirety of the reflux process. It is therefore proposed as future work that the use of a dry
solvent be investigated to determine if the presence of water within the system has any e↵ect
on the yield of the reaction. One further aspect noted it that the starting material used for
microwave synthesis of the Ru cylinder contains ruthenium in a 3+ oxidation state, as opposed
to the 2+ oxidation state as found in [Ru(DMSO)4Cl2]. The use of a di↵erent Ru(II) starting
material was considered for microwave synthesis, but as many of the simple Ru(II) compounds
available are derivatives of [Ru(bpy)3]
2+, it does not seem reasonable to assume that one Ru N6
chromophore would be broken to form another. The investigation of di↵erent ruthenium starting
materials is therefore also proposed as future work but, as the aim of this work was not solely
focused on improving synthetic protocols, these options were not pursued further here.
2.3 Improving purification protocols for Ru cylinder
As well as investigating methods to improve the synthesis of Ru cylinder, this work also
presents attempts to improve the purification protocol. As discussed above, one consistent
problem is the production of Ru(III) by-products, observed as paramagnetic material in NMR
spectra which are not removed by chromatography. It was hypothesised that attempting to re-
duce any Ru(III) by-products to Ru(II) material may make separation more successful by chang-
ing the way that the species interact with the silica of the chromatography column. Therefore
N-ethylmorpholine was used as a reducing agent, as previously seen in literature [68, 69, 70].
This procedure was introduced into the protocol after the first silica chromatography column,
following the removal of the majority of the unwanted material. Following protocols as seen
in literature cited above, the crude reaction material was dissolved in methanol and then heated
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before adding 2 ml of N-ethylmorpholine. Methanol was used as the solvent to allow for it to
be oxidised to methanal as part of the redox reaction. This step led to the removal of much of
the by-product, as shown by 1H NMR spectra in Figure 2.2.
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Figure 2.2: 1H NMR spectra of Ru cylinder before (top) and after (bottom) re-
duction with N-ethylmorpholine in methanol. The spectra show how this process
led to the removal of much of the impurities initially seen within the 1H NMR
spectrum. 49
Whilst the use of N-ethylmorpholine removed some of the impurities seen in 1H NMR spec-
tra, it is clear that further column chromatography was still required to remove the remaining
impurities. However, subsequent silica chromatography columns failed to remove any more
impurities, showing that the use of this reducing agent did not further improve the purification
protocol and so this was not investigated any further.
This work also presents investigations made to improve the column chromatography protocol
for Ru cylinder, as the current protocol of silica chromatography is both time consuming and
leads to large loss of product as it readily adheres to the silica. The use of Sephadex C-25
resin has been investigated and has been found to be more time-e cient. As the Sephadex resin
must be prepared in aqueous solution, the crude [Ru2L3]
4 must also be soluble in water. When
complexed with (PF6) counter-ions, the Ru cylinder is only soluble in acetonitrile or acetone,
so it was necessary to complete an ion-exchange process. A protocol for this process had
already been established as part of the published synthesis so this was used without alteration
- the crude [Ru2L3](PF6)4 was dissolved in acetone and added to t-butylammonium chloride
(also dissolved in acetone). This allows the chloride ion to replace the (PF6) counter-ion to
give a final complex of [Ru2L3]Cl4. This complex in insoluble in acetone, so precipitates from
solution and can be collected by filtration. Using the Sephadex columns, pure product can be
eluted using increasing concentrations of NaCl in water. Pure [Ru2L3]Cl4 was eluted using 0.4
M NaCl. A second Sephadex column was usually required, again eluting with 0.4 M NaCl in
water. This strategy proved to be more time e cient as it only required two chromatography
columns to be used, but is does not lead to an increased yield of final product. Therefore either
Sephadex C-25 or silica column chromatography were found to be suitable for purification of
Ru cylinder.
2.4 Fluorescent properties of Ru cylinder
As discussed in Chapter 1, the attraction of using Ru cylinder to determine the cellular locali-
sation of this class of compounds is the fluorescent properties of the Ru cylinder. The absorption
50
and emission spectra of [Ru2L3]Cl4 are shown in Figure 2.3. These show that the MLCT of the
ruthenium cylinder has a maximum at 484nm and, when excited at this wavelength, gives an
emission spectrum with a maximum at 690nm.
Figure 2.3: Absorption and emission spectra of Ru cylinder recorded in DMEM
media normalised to one at the point of maximum absorption or emission. The
absorption spectrum shows MLCT centred at 484nm, with maximum emission
at 690nm
The emission recorded from [Ru2L3]Cl4 is found in the far-red portion of the electromag-
netic spectrum. This is in line with other Ru N6 chromophores, the most notable of these
compounds is [Ru(bpy)3]
2+ - tris(bipyridine) ruthenium(II). [Ru(bpy)3]
2+’s emission is however
centred at 630nm, so there is a notable red-shift in light emitted by [Ru2L3]
4+. This change
has previously been attributed to the pyridylimine ligand having a ⇡* orbital at a lower energy
than that observed in the pyridine ligand [71]. Combined with the recorded absorption profile,
it is expected that [Ru2L3]
4+ will be suitable for both fixed and live cell imaging. The MLCT
occurs at 484nm - a wavelength which is outside the UV range and so exciting here will not the
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cause severe damage to cells during live cell imaging that is associated with UV light. It also
means the MLCT can be e ciently excited using a commonly available 488nm argon laser. The
emission profile is also favourable as any emission seen at 690nm during cell imaging should
be directly attributable to [Ru2L3]Cl4 as cellular autofluorescence is not known to be observed
in this region. With a suitable synthetic protocol established, imaging experiments began.
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Chapter 3
Investigating the cellular localisation of
cylinders
3.1 Developing a suitable imaging protocol
As no cytotoxicity data for MDA-MB-231 cells treated with [Ru2L3]
4+ had been collected, de-
veloping a suitable imaging protocol was the first aim of this work. Previous work in the group
suggested that treatment of the same cell line with [Fe2L3]
4+ led to a disruption in cell motil-
ity, and caused cells to ‘ball up’. However, when MDA-MB-231 cells are treated at the same
concentration for the same amount of time, results of an MTT assay show that the cells are still
viable [14], so imaging alone of [Ru2L3]
4+ treated cells cannot determine which cells are simply
changing morphology due to the e↵ects of cylinder and those which have entered apoptosis. It
was therefore decided to perform an assay to determine how viable MDA-MB-231 cells are
after treatment with increasing concentration of ruthenium cylinder. The ToxiLight BioAssay
was selected as it is a straightforward and highly sensitive assay. It works by detecting the
presence of adenylate kinase (AK) in cell media. AK is a phosphotransferase enzyme found
in all mammalian cells, and will only be found in cell media when the membrane of cells has
been compromised and so has leaked into the surrounding media. AK catalyses the intercon-
version of two molecules of adenosine diphosphate (ADP) to one molecule each of adenosine
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triphosphate (ATP) and adenosine monophosphate (AMP);
Mg2+-ADP + ADP
AdenlyateKinase           !Mg2+-ATP +AMP
This assay utilizes a second enzyme, luciferase, which catalyses the formation of light from
ATP according to the following reaction;
ATP + Luciferin + O2
Luci f erase       !
Mg2+
Oxyluciferin + AMP + PPi + CO2 + light
The intensity of light emitted is therefore linearly related to the levels of AK in the cell media,
which can then be taken as a measure of the level of cell viability.
Cells were treated with 12.5, 25, 50 or 100 µM [Ru2L3]
4+ and positive or negative control
samples were also prepared. A 100% Lysis Reagent was used as the positive control and a tris-
acetate bu↵er was used for the negative control both of these reagents were supplied with the
assay kit. Three 30 µL aliquots of cell media were taken at zero, two, four and six hours. This
was then added to AK detection reagent in a 96-well plate, and luminescence was recorded on
a TECAN GENios Multifunction Microplate reader. The average of the three readings taken at
each time point was then calculated and corrected for background luminescence from the AK
detection reagent alone. The percentage viability was then defined as;
[(Positive control   averaged reading)/Positive control] ⇥ 100
The averaged luminescence value of the positive control sample after 6 hours was taken as
the positive control value, as all cells would be completely lysed by this time point. Data is
presented in Figure 3.1 on page 55.
These results show that there appears to be little or no cytoplasmic membrane damage in-
duced by these concentrations of cylinder over this time-scale. this suggests that the change in
morphology observed during imaging using these time-scales and concentrations is not due to
apoptosis and therefore appears to reinforce the findings of the previous work with [Fe2L3]
4+.
Control experiments performed with [Ru2L3]
4+ added to cell lysates produced surprising re-
sults. Increasing concentrations of [Ru2L3]
4+ lead to decreasing luminescence, suggesting that
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Figure 3.1: The cytotoxic affect of [Ru2L3]
4+ on MDA-MB-231 cells as deter-
mined by Toxilight assay. The data points are the mean and standard deviation
of three experiments (n=3) carried out in quadruplicate.
[Ru2L3]
4+ inhibits the production of light during the assay. Further control experiments with
cell lysates showed that the inhibition is a function of a complete cylinder and not free ligand L
or metal, as shown in Figure 3.2 and Figure 3.3 on page 56.
It was therefore decided that the Toxilight assay was not suitable for developing an imaging
protocol. Based on previous work using MTT assay to determine the toxicity of [Ru2L3]
4+ [14]
[42], it was decided to use 100 µM treatments for imaging studies as this had been shown to not
be toxic over the short time frame used for imaging experiments.
3.2 Fluorescence microscopy of cylinders within cells
3.2.1 Imaging Ru cylinder using confocal fluorescence microscopy
Confocal microscopy has been utilized in order to image [Ru2L3]
4+ within MDA-MB-231
cells. As the cylinder is known to have its maximum emission at 705nm, emission was col-
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Figure 3.2: The inhibition of light produced during Toxilight assay using cell
lysates treated with increasing concentrations of [Ru2L3]
4+. The data points are
the mean and standard deviation of triplicate experiments.
lected between 680-720nm, following excitation at 484nm. Control samples of untreated cells
were imaged, as were cells treated for both 1.5 and 4 hours respectively. Cells treated for 1.5
hours clearly show cellular uptake of the compound, but no clear evidence of nuclear localisa-
tion, shown in Figure 13. Areas of fluorescence corresponding to the appearance of vesicles
surrounding the nuclear membrane suggest either an endocytosis uptake mechanism, or the
‘packaging’ of the compound once within the cell. The images taken of samples treated for 4
hours show similar results, with no clear nuclear localisation observed, but again distinct areas
of fluorescence corresponding to vesicles could be seen, shown in Figure 3.4.
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Figure 3.3: Control experiment for Toxilight assay with cell lysates treated with
ligand L, RuCl3 · xH2O and [Fe2L3]4+ showing that light production is only inhib-
ited by the cylinder structure, not its components. The data points are the mean
and standard deviation of triplicate experiments.
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Figure 3.4: Images of [Ru2L3]
4+ in MDA-MB-231 cells, at time points 1.5 hours
(top row) and 4 hours (bottom row). Scale bar indicates 10 µm, and intensity
bars correlate to detected fluorescent counts.
The images shown in the bottom row of Figure 3.4 was recorded as part of a Z-stack experi-
ment where confocal images are recorded at intervals throughout the volume of the cell. It was
then possible to use these images to produce an image to show the average fluorescence signal
in the cell. An image showing the average fluorescence detected is shown in Figure 3.5.
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Figure 3.5: Image showing the average fluorescence of [Ru2L3]
4+ in MDA-MB-
231 cells. Scale bar indicates 10 µm, and intensity bars correlate to detected
fluorescence counts.
The fluorescence signal across the cell is very weak, and there is a comparable level of
noise within the image. However the strongest signal seen is that from within the cell, and it
does strongly suggest that [Ru2L3]
4+ is taken into MDA-MB-231 cells and leads to a fluorescent
signal. The fluorescence signal is not evenly distributed across the cell suggesting some degree
of localisation within the cell.
After observing Ru cylinder within MDA-MB-231 cells, attempts were also made to image
the cylinder within SKOV-3 ovarian cancer cells. Previous toxicology work within the group has
shown that the Ru cylinder is inactive against SKOV-3 cells whilst the Fe cylinder has toxicity
within one order of magnitude of cisplatin [14]. Imaging of cells treated with Ru cylinder for 4
hours revealed that no fluorescence was observable from within the SKOV-3 cells (as shown in
Figure 3.6) suggesting that the Ru cylinder is inactive as it does not enter the cells or because it
is immediately broken down once inside the cell.
Therefore MTT data was acquired to determine if free ruthenium metal is toxic to MDA-MB-
231 or SKOV-3 cells - if it is proved to be toxic then it can be said that the viability of the cells
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following cylinder treatment indicates that the cylinder is not broken down within the cell.
Figure 3.6: Image of SKOV-3 cells treated with [Ru2L3]
4+ for four hours, showing
brightfield image (left) and fluorescence image (right), however no discernible
fluorescence signal was observed. Intensity correlate to detected fluorescence
count.
MTT assay work has already shown that free ligand is not toxic to cells [42]. Data collected
here now shows that free ruthenium is also non-toxic to SKOV-3 and MDA-MB-231 cells, as
determined using Student’s t-test, at a confidence of P < 0.05. This means it cannot be said for
certain whether the cylinder enters SKOV-3 cells and is then broken down, or does not enter the
cell at all. It also raises the possibility that the low levels of fluorescence seen in MDA-MB-231
cells may be caused by [Ru2L3]
4+ being taken into cells and then being metabolised, losing the
Ru-N6 chromophore. The results of the MTT assays are presented in Figure 3.7.
3.2.2 Imaging fluorophore-tagged cylinders using an integrated UV-Vis
spectrometer/brightfield microscopy system
As observing the cylinder within cells proved di cult due to the low quantum yield of the
cylinder, work began on attaching a fluorophore to the parent ligand, L. The aim of this was to
improve visualisation of the cylinder within cells, whilst remaining aware that the addition of
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Figure 3.7: MTT data of RuCl3 · xH2O showing that it is not toxic for MDA-MB-
231 or SKOV-3 cancer cells. Data shows mean and standard deviation (n=3) or
triplicate experiments, each experiment was performed in quadruplicate. Stu-
dent’s t-test analysis using P=0.05 showed that there was no statistically signifi-
cant difference between the population treated with RuCl3 · xH2O and those left
untreated.
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any fluorophore to the cylinder would clearly alter the cylinder’s size, shape and could also im-
pact on the cylinder’s DNA binding properties. The ideal fluorophore would therefore be small
enough to not interfere with the cylinder’s DNA binding properties and have fluorescent prop-
erties suitable for cellular imaging. Anthracene was chosen as it is small, has a high quantum
yield, absorption and emission removed from cellular autofluorescence and an usual emission
spectrum which would be easily identified within a sample. Using synthetic routes previously
developed within the group [72], a synthetic route for attaching commercially available 2-amino
anthracene to the C5 position of ligand L’s terminal pyridine group was devised, and ultimately
[Cu2L
Ant2]2+] cylinder was synthesised within the group [73]. Due to the large size of this
compound it was only soluble in DMSO, limiting its usefulness as an imaging probe as the
presence of DMSO is toxic to cells on its own. The low yielding reaction also meant that there
was not enough compound to perform toxicology and imaging studies, so as a first attempt at
imaging, MDA-MB-231 cells were treated with 100µM anthracene-tagged cylinder for 4 hours,
fixed using paraformaldehyde and mounted onto microscope slides before being imaged using
a novel integrated UV-Vis spectrometer and brightfield microscope system. Recorded images
are shown in the top and middle rows of Figure 3.8.
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Figure 3.8: MDA-MB-231 cells imaged using an integrated UV-Vis spectrometer
and brightfield microscope system. Top row shows control brightfield and cor-
responding fluorescence images, middle row shows cells treated with 100µM
anthracene-tagged cylinder and bottom row shows cells treated with 100 µM
amino-anthracene. Both treated samples show observable fluorescence follow-
ing excitation at 342nm however those treated with anthracene-tagged cylinder
show a clear change in morphology. Scale bar indicates 50 µm.
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The control samples show the expected cell morphology of MDA-MB-231 cells, with the
known ’spindle-like’ morphology clearly observable in the brightfield image. The correspond-
ing fluorescence image shows no cellular autofluorescence following excitation at 342nm.
Treatment with the copper cylinder shows a clear induced change in morphology and also a
decrease in cell density on the surface. The corresponding fluorescence image shows bright
fluorescence within cells, although not localised to any definable region. Exciting at the MLCT
from copper to ligand ( ex = 540nm) led to no observable fluorescence.
As this is a new cylinder, it was not known how stable this compound would be. As such,
imaging studies continued using amino-anthracene instead of cylinder. It was believed that the
spectra of bound and free anthracene within cells would di↵er due to the extended conjugation
system of the cylinder. Therefore images and emission spectra were recorded of MDA-MB-
231 cells treated with amino anthracene and are presented in the bottom row of Figure 3.8.
Comparing spectra for control, cylinder-treated and anthracene-treated samples with the spectra
of anthracene cylinder in DMSO solution (as shown in Figure 3.9), it is clear the cylinder treated
samples retain the characteristic finger-print spectra of the anthracene cylinder, whereas the
samples treated with amino-anthracene show an broad extra peak centred around 500nm.
From the recorded images and emission spectra, it is believed that the anthracene remains
bound to the ligand within cells. However it was not known how stable a double-stranded cop-
per cylinder would be, and if the cylinder was remaining as one structure within cells. So the
stability of copper cylinders was investigated using UV/Vis absorption spectrometry. Due to
the di culty and low yielding synthesis of the anthracene cylinder, the studies were performed
using the a copper cylinder synthesised using the parent ligand - [Cu2L2]
2+, which has previ-
ously been synthesised within the group [74]. The absorption spectrum of [Cu2L2]
2+ shows
absorbance at 240nm, 330nm and 505nm, with the absorbance at 505nm due to the MLCT. The
absorption spectra of [Cu2L2]
2+ is shown in Figure 3.10.
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Figure 3.10: Absorption spectrum of [Cu2L2]
2+.
Stability studies (performed by recording UV-Vis spectra of a compound over 12 hours in
solution and observing any change in absorption bands) show that [Cu2L2]
2+ does not fall apart
in solution during the time scale measured, the resulting spectra are shown in Figure 3.11 - only
the spectra recorded at 0 and 12 hours are shown for clarity.
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(a) Spectra of region 220-280nm
(b) Spectra of region 420-590nm
Figure 3.11: Stability studies of [Cu2L2]
2+ (Parent cylinder). Spectrum at 0 hours
shown in blue and spectrum at 12 hours in red. Spectra for the region 220-
280nm (top image) and 420-590nm (bottom image) show that [Cu2L2]
2+ does
not fall apart in solution.
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The anthracene modified ligand has been been shown to remain intact within MDA-MB-
231 cells, but as no fluorescence resulting from a metal-ligand transition has been observed, it
cannot be said that the cylinder structure as a whole is intact within the cells. However stability
studies with other double helicate copper cylinders show that this general structure is stable.
Previous work within the group to attach peptides to the triple stranded iron cylinder [72]
showed that the modified cylinder had increased toxicity and actually stabilised the DNA three-
way junction compared to the parent cylinder. Work of this type must be performed to determine
if the addition of the anthracene has altered the DNA binding that was previously observed for
double stranded copper cylinders [75].
3.3 Co-localisation of cylinders with cellular dyes
Another strategy investigated for determining the cellular localisation of cylinders was to look
for co-localisation of cylinder fluorescence with organelle specific dyes. Using this strategy
gave two possible ways of looking for cylinder localisation;
• Co-localisation of dye and cylinder fluorescence
• Decreasing dye emission with increasing cylinder concentration   suggesting the cylinder
is either quenching or displacing the dye.
3.3.1 Studies with Hoechst nuclear dyes
The nuclear dye investigated was Hoechst 34580. This was chosen as it is an easy to use
dye with attractive fluorescence properties. Although its maximum absorption is at 375nm,
it can be e ciently excited using a readily available 405nm laser, and has emission centred
around 450nm when bound to DNA. This gives Hoechst 34580 another attractive property  
the possibility of engineering a Forster Resonant Energy Transfer (FRET) experiment. The
long tail observed on Hoechst 34580 means that the ruthenium cylinder should absorb in the
region Hoechst emits. It was hoped that by exciting at 405nm, fluorescence could be observed
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in the 680-720nm region and therefore be attributed to the cylinder. This o↵ered a third way
of showing any nuclear localisation of cylinder, in addition to those described above. MDA-
MB-231 cells were treated with 0.4 µg/mL Hoechst 34580 for 25 minutes followed by 4 hours
treatment with 15 µM [Ru2L3]
+
4 and imaged live using confocal microscopy. Figure 3.12 shows
a control experiment of cells treated solely with Hoechst 34580, and it is clear that the tail of
the Hoechst emission spectrum is still detectable between 680-720nm - the area where it was
hoped FRET fluorescence from the ruthenium cylinder would be detected.
(a) Emission recorded between 440-460nm (b) Emission recorded between 680-720nm
(c) Corresponding brightfield image (d) Overlay of images (a-c)
Figure 3.12: Images of MDA-MB-231 cells stained with Hoechst 34580 nuclear
dye.
Figure 3.13 shows the images collected of cells following treatment with ruthenium cylinder,
which were recorded under the same conditions as those shown in Figure 3.12.
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(a) Emission recorded between 440-460nm (b) Emission recorded between 680-720nm
(c) Corresponding brightfield image (d) Overlay of images (a-c)
Figure 3.13: Images of MDA-MB-231 cells stained with Hoechst 34580 nuclear
dye and then treated with [Ru2L3]
4+.
It was however noted that the fluorescence appeared to decrease following treatment with the
cylinder, so analysis of both sets of images was undertaken to see if an decrease in fluorescence
could be observed following cylinder treatment. Taking a simple average mean pixel intensity
across the whole image is not a reliable approach as this does not take into account the number
of cells in each image   images containing large areas of background could artificially decrease
the mean pixel intensity. To combat this a simple algorithm was constructed to threshold the
fluorescence images into binary images where pixels of an intensity above that found in the
control images were given a value of 1, and all other pixels took a value of 0. Determining the
mean pixel intensity of the thresholded pixels in the original image gives a much fairer reflection
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of the average fluorescence intensity for each sample. The calculated average intensities are
presented in Figure 3.14.
Figure 3.14: Average pixel intensity of fluorescence images of MDA-MB-231
cells treated with Hoechst 34580, with  ex = 405nm. The red and blue bars are
controls, showing average intensity between 440-460nm and 680-720nm re-
spectively. The green and purple bars show average pixel intensity between the
same ranges following treatment with [Ru2L3]
4+. Error bars indicate one stan-
dard deviation (n=3) from the mean pixel intensity. A Student t-test at p=0.05
showed that the difference between recorded fluorescence at each wavelength
is statistically significant.
The average pixel fluorescence intensity is shown to decrease following treatment with
cylinder, but emission recorded between 440-460nm in control and treated samples lie within
a standard deviation of each other, so it cannot be said that the decrease is statistically signifi-
cant, and so no further analysis of this data is presented here. It is also noted that, the images
analysed here were acquired by confocal microscopy as a proof of principle, and so there is
the possibility that the change in fluorescence seen is due to the location of the plane in focus
within the cell. As such, Z-stack experiments over a series of cells would give the total level
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of fluorescence within them, and lead to a fairer comparison. This line of investigation was not
pursued further in this work, but was instead taken forward within the group - Z-stack images
of cells treated with Hoechst dye and then treated with the Fe cylinder showed a significant
decrease in Hoechst emission, showing that the Fe cylinder was able to displace Hoechst dye
[76].
3.4 Using synchrotron radiation to detect cylinders within
cells
3.4.1 Principles of XANES and XRF spectroscopy
X-Ray Absorption Near-Edge Spectroscopy (XANES) is a technique for measuring the interac-
tions between core-shell electrons. It uses lower energy than related technique Extended X-ray
Absorption Fine Spectroscopy (EXAFS), and involves the excitation of core electrons to the
Lowest Unoccupied Molecular Orbital (LUMO). The movement of the electrons between or-
bitals will occur at a defined x-ray energy for each transition, and so at the point when a large
increase in absorption is observed, the electronic transition caused by the incident x-ray can be
deduced. This means that properties such as the oxidation state of the atom, and the identity of
any bonded atoms can be identified [77].
Synchrotron radiation can also be used to gather information about the cellular localisation
of elements within a sample. This is done using the technique of X-Ray fluorescence (XRF)
spectroscopy. Of course following excitation of an electron due to absorption of an x-ray, there
must be a decay mechanism to return the atom to its ground state. The fluorescence caused by
this decay is again characteristic for each element, and so by recording the fluorescence spec-
trum at hundreds of discrete locations across the sample allows for the simultaneous detection
of all elements within the detection range. By then assigning each spectrum to a pixel within an
image, maps showing the distribution of each element are produced.
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3.4.2 Examples of compound investigation using synchrotron radiation
Synchrotron radiation is particularly useful for the investigation of compounds because of the
ability to detect elements at low concentrations, and also the ability to detect multiple elements
in one measurement.
X-Ray Absorption Spectroscopy (XAS) has been utilised to probe the interactions between
NAMI-A and bovine serum albumin (BSA), prompted by the results of Phase I clinical trials
suggesting NAMI-A was found in the blood plasma of patients [33]. A technique such as X-
Ray Absorption Spectroscopy (XAS) is ideal for investigating a ruthenium compound within
biological samples as the ruthenium identified can only be attributed to the compound. By using
XANES, Ascone et al. have been able to show that the ruthenium centre of NAMI-A remains at
a 3+ oxidation state following binding to BSA, with the chlorine environment most significantly
changed [78].
Following on from this, Lay et al. have used synchrotron radiation to investigate the cellu-
lar e↵ect of KP1019 and NAMI-A within liver cancer cells [79]. This work corroborated that
NAMI-A forms several adducts with serum albumins. Interestingly, it was concluded that the
XAS spectra of NAMI-A and an eqimolar amount of BSA was not significantly di↵erent from
the spectra obtained when KP1019 was combined with BSA, with substitution of chlorine lig-
ands on both compounds leading to binding to the protein. A further interesting conclusion was
the observation that KP1019 appears to decompose when left for 4 hours in serum-enhanced
media. This lead to a 50% decrease in uptake of ruthenium into liver cells than compared to
cells treated with a ‘fresh’ solution of compound, whilst low levels of ruthenium were found in
samples treated with NAMI-A, again reinforcing the hypothesis that NAMI-A’s e↵ectiveness is
not due to a cellular uptake.
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3.4.3 Examples of cellular imaging using synchrotron radiation
The applicability of synchrotron radiation for the use of imaging cells was beautifully demon-
strated by McRae et al. who used the technique to map the elemental distribution of metals in a
cell undergoing mitosis, and were able to show that cellular levels of zinc almost treble during
mitosis [80]. The use of synchrotron radiation to image compounds within cells was compre-
hensively reviewed by [81] in 2007. Since then, there have been several more examples of
synchrotron radiation being used to image metallodrugs within cells, such as [82] and [83]. Of
particular relevance to this work, imaging studies have also been used to conclude that NAMI-A
is not taken up into neuroblastoma cells SH-SY5Y [13]. Images obtained by Aitken et al. (us-
ing XRF at Advanced Photon Source, 2-1D-D, Chichago at an energy of 22.5 keV) are shown
in Figure 3.15. By studying elemental co-localisation, it was determined that the ruthenium
taken into the cells was coincident with areas of high phosphorus concentration, suggesting the
ruthenium is delivered to the nucleus. The area of high phosphorus concentration is taken to
be the nucleus as the phosphate backbone of DNA would be the main site of phosphorus found
within the cell.
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Figure 3.15: Brightfield image and elemental maps for a) untreated SH-SY5Y
cells, b) SH-SY5Y cells treated with KP1019 and c) SH-SY5Y cells treated with
NAMI-A. For all images, the element mapped is shown in top left corner where
SA denotes absorption from scattered x-rays. All images reproduced with per-
mission from Figures 1,2 and 4 in [13]
3.4.4 Using synchrotron radiation for imaging of cylinders
All imaging experiments described so far show fluorescence that has been attributed to the
cylinder but these experiments do not allow for any chemical information about the cylinder to
be gathered. If elemental maps of cellular samples treated with [Ru2L3]
4+ can be obtained, these
could be an excellent complement to the confocal fluorescence microscopy images presented
earlier. The elemental mapping of cells can also reveal the location of cell organelles, for
example an area of zinc and phosphorus co-localisation is considered to be a good indicator of
the concentration of zinc fingers proteins expected to be found within the nucleus. This allows
imaging experiments to be taken a stage further from work already performed - if any ruthenium
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could be detected within a cellular sample, it may be possible to determine a discrete cellular
location.
Also, the uptake mechanism of the iron cylinder may be able to studied using this approach.
Many iron compounds are known to enter cells via the transferrin uptake pathway, which has
several mechanisms, but receptor-mediated endocytosis of transferrin is the most understood
[84]. The iron-free form of transferrin, apotransferrin, binds two Fe(III) ions to form ferrotrans-
ferrin. All cells express transferrin receptors and cancer cells have been shown to have elevated
expression of the receptor compared to health cells [85]. At physiological pH, ferrotransferrin
binds strongly to the transferrin receptor to initiate its internalisation via endocytosis. Once
inside the acidic (pH < 6) late endosome compartment, the two Fe(III) ions are dissociated
from ferrotransferrin (which now becomes apotransferrin again) and transported into the cy-
tosol [86]. The apotransferrin remains bound it the transferrin receptor and is recycled at the
cell membrane. This protein-ligand bond is unstable at pH values above 6 and hence the apo-
transferrin dissociates away from the receptor at the cell membrane, which is then free to bind
to a new ferrotransferrin molecule. If it can be shown that iron at the membrane is only found in
+2 oxidation state, then uptake of the iron cylinder by the transferrin pathway seems unlikely.
With the aim of imaging both ruthenium and iron cylinders within cells and producing
XANES spectra of areas of metal concentration, work began on the I18 beamline at Diamond
Light Source Synchrotron, which has already been used to study metals within breast cancer
tissue [87]. Limits of detection on this beamline under the most optimal conditions has not
been tested for every element, but it is estimated that the detection limits for transition metals
would be high parts per billion (ppb) /low parts per millions (ppm) [88]. One ppm is taken as
an estimate as this is the typical metal concentration in the reference standards used for evaluat-
ing XRF limits, and so detection limits equate to approximately Fe = 18 µM, Ni = 17µM, Ru =
10µM. As the cells to be imaged here are to be treated with 100 µM of cylinder, and the cylinder
containing two metal atoms, the e↵ective concentration of the elements of interest will be 200
µM, so the quantity of element present should not be a limiting factor on the ability to detect it
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within these samples. The ability to detect elements of interest at low concentrations is largely
due to brilliance of the X-ray beams provided the synchrotron and the ability to focus the bright
light to micron-sized dimensions. This has the e↵ect of increasing the photon flux delivered
to the sample, dramatically increasing the number of X-ray element interactions per second.
The ability to focus the incident beam to a spot size of known dimensions also permits sensitive
spatially resolved mapping of elements. Since the monochromater enables the X-ray energy
and bandwidth to be tuned, the excitation conditions at the sample can be altered to maximise
the chance of detecting a particular element amongst a background of other elements. This can
be achieved, for example, by tuning the monochromator to output a beam of a very narrow en-
ergy range centred about a particular transition energy for the element of interest. Conversely,
varying the focus of the beam will change the flux density of photons incident on the sample as
the same number of photons are distributed over a di↵erent sized area, and this would reduce
the detected signal over the same measurement period and hence reduce sensitivity.
3.4.5 Sample Preparation
Two sample preparation methods were initially investigated - freezing cells grown directly on
quartz or embedding samples within resin following a protocol as described in [89]. Freezing
cells directly on the surface they were grown on allows the cells to grow to their natural size
and shape, and removes the need of any chemical fixative which could suppress any signal from
our sample. However there are no literature reports of attempting to fix these cell lines using
freezing so it was not known if this method of sample preparation would alter the cell mor-
phology or even detach the cells from their substrate. Embedding cells in resin is a much more
widely used technique as it is routinely used in the preparation of electron microscopy samples.
However, this preparation method involves detaching the cells from their growth surface and
using gluteraldhyde fixatives which ideally would be avoided, due to their slow fixation rates
and ability to react with free amines within the cell. Detaching the cells also causes them to
contract in size and so taking sections of the resin runs the risk of missing the cells completely
or taking a section of only the very edge of a cell.
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Initially, two cell lines were investigated, MDA-MB-231 and A2780. Samples were grown
on quartz slides, with silicon rings being used to define the cell growth area. Cells were left
to adhere for 24 hours before being treated with cylinder. The cells were only treated for two
hours, as treatment with any longer may have resulted in cell death which would have lead to
a narrow scope of cell imaging experiments. The slides were then frozen by plunging in CO2
cooled acetone. Once frozen, samples were stored at -20 C until required for imaging. Resin
embedded samples were prepared by growing cells in 6-well plates and treating with cylinder
before detaching the cells using trypsin and spinning them into a pellet before re-suspending in
gluteraldehyde. Cells were left in the fixative overnight before being embedded in resin by Dr
Paul Stanley at the Centre for Electron Microscopy, University of Birmingham.
3.4.6 Initial Results
Optical imaging of the samples were acquired using an Olympus reflected light microscope
prior to imaging on the beamline. These showed that almost no MDA-MB-231 cells had ad-
hered to the quartz slides, and very few A2780 cells could be observed. The slides had been
checked prior to freezing, and adherent cells had been observed so it was determined that the
freezing process had caused many of the cells to detach. Improving the freezing protocol was
therefore highlighted as future work. Once the samples had been inserted into the beamline, op-
tically observing the cells became problematic due to the requirement to place an Ultralene film
over the sample for health and safety reasons. The film is a simple hydrocarbon, with formula
C4H4, meaning that there was no potential for any signal from the film to be mistaken for signal
from the cylinder. The film did however allow for monitoring of the location of the beam which
scorched the film while rastering across the sample, making it straightforward to align the beam
with the microscope image. All beamline work with MDA-MB-231 samples confirmed that no
cells were present on the quartz slides, so e↵orts concentrated on A2780 samples. Elemental
maps were obtained of areas showing strong co-localisation of calcium, zinc, potassium, iron
and chlorine - elements that are routinely found within cells.
78
3.4.7 Further Development of Imaging Protocol
To overcome the sample preparation problems that were encountered during the first experi-
mental run, modifications to the original sample protocol were investigated, as well as the use
of a new substrate - silicon nitride windows. The silicon nitride windows have been used in
several published articles [13], [90] and [91] and it was hoped the new substrate would allow
for improved growth of both MDA-MB-231 and SKOV-3 cells.
The silicon nitride windows were used by placing them in 6-well plates before cell and media
were added. Inspection of the wells using light microscopy showed that cells began to adhere
to the windows within two hours of being added. Whilst the silicon nitride windows were an
excellent growth substrate, their fragile nature made them di cult to handle.
Therefore modifications to the protocol of growing cells on quartz were investigated. It was
decided to coat the quartz slides with a protein prior to adding cells in the hope of promoting cell
adherence. Coating the slides with foetal bovine serum (FBS) lead to improved adherence of
SKOV-3 cells, but did not lead to any adherence of MDA-MB-231 cells. Coating with collagen
however lead to adherence of both cell lines upon the quartz slides, which meant that it was
now possible to prepare samples on both quartz and silicon nitride to investigate any di↵erences
between growth substrate. It was noted that the elemental maps of cells grown on collagen
coated slides show high levels of zinc across the slide, believed to be due the metalloproteases
found within collagen. This however could be used as a good negative contrast for confirming
the presence of cells on a slide.
The final modification to cell preparation was to alter the freezing process by changing the
freezing medium to dry ice cooled methanol as opposed to acetone. As methanol is commonly
used as a cell fixative this seemed a sensible choice and no noticeable detachment of cells was
caused by the freezing process. All samples were therefore frozen using this method.
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The imaging of samples was a two stage process - firstly the slide was imaged optically
using a Zeiss confocal microscope, in order to find an area of cells suitable for imaging on the
beamline. The co-ordinates of this position were noted, meaning that it was easy to find the
relevant area once the sample was inserted into the beamline. A beam of approximately 2x5
µm was used to map areas of the order of 200 x 200 µm2 allowing the localisation of a number
of cells per slide. A beam energy of 11 keV was used for all mapping studies. This energy
allows simultaneous detection of the cylinder metals but also the endogenous elements that
help confirm the location of the cells in the surrounding matrix (eg Cl, Ca and Zn). Photographs
of the experimental set up are shown in Figure 3.16. Previous attempts at imaging were limited
by the need to use Ultralene film, following consultation with Dr Tina Geraki, Diamond Light
Source, it was not deemed necessary to use this film for any of the samples used from this
point onwards, and so all samples shown below were recorded without the presence of any
film/coating on top of the sample. A helium cryojet was also now available, which meant it was
possible to maintain the samples as frozen during the data acquisition process.
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Figure 3.16: Images of experimental set up at I18 beamline. Left - view of
experimental hutch, facing towards the beamline. Right - Rear (top) and forward
facing (bottom) views of sample in situ. The blue pipe blows cooled nitrogen to
the rear of the sample, the thinner outlet in the bottom right image is a helium
cryojet - both of these are to keep the sample cold. The large apparatus seen
in the bottom right image is the detector, held at 45  to the sample.
Control samples of SKOV-3 cells grown on quartz were imaged to gain an understanding of
the elemental distribution and levels in an untreated sample. Elemental maps and an optical
image of cells are shown in Figure 3.17.
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(a) Optical image (b) Fe map
(c) Ca map (d) Cl map
(e) Cu map (f) K map
(g) Zn map (h) Ni map
Figure 3.17: Elemental maps and optical image of control SKOV-3 cells, which
were grown on quartz following FBS coating. Scale bar represents 10 µm, in-
tensity bar represents detected fluorescence photon count rate. The gating of
all detected fluorescence to each element was performed by Dr Tina Geraki of
Diamond Light Source.
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The control images show that elements such as calcium, chlorine, copper, potassium and zinc
can be seen as clearly localised within the cells. Unsurprisingly, nickel is seen in low levels and
the levels found within the cells do not appear to be significantly higher than the surrounding
area. More surprisingly, the elemental map of iron is very similar to that of nickel. As tumour
cells are known to have more transferrin receptors than healthy cells, it was expected that the
control elemental map would contain high levels of iron and would also be able to used to
‘mark’ the position of the cell. However, there is a converse argument that cancer cells are
particularly active, and so have low levels of iron at any one time, so this observation of low
levels of iron appears to support the second hypothesis.
Following collection of control data, attention turned to imaging SKOV-3 cells treated with
iron cylinder. Images collected of a SKOV-3 cell treated with iron cylinder having been grown
on a silicon nitride window are shown in Figure 3.18.
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(a) Optical image (b) Fe map
(c) Ca map (d) Cl map
(e) Cu map (f) K map
Figure 3.18: Elemental maps and optical image of SKOV-3 cells grown on Si3N4
windows, and then treated with [Fe2L3]
4+ cylinder. Scale bar represents 10 µm,
intensity bar represents detected fluorescence photon count rate. The gating of
all detected fluorescence to each element was performed by Dr Tina Geraki of
Diamond Light Source.
As per the control images, elements such as calcium and chlorine clearly show the location
of the cell. Whilst all other elemental maps are shown on linear scale, the iron map is shown in
logarithmic scale for clarity. It is clear that there are increased levels of iron within the cell, and
a noticeable ‘hot spot’ of iron present at the cell membrane. This area appears to coincide with
a vesicle that can be seen at the membrane of the cell in the optical image.
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XANES scans were performed on the area of high iron concentration to determine the oxi-
dation state of the Fe. This proved to be very problematic as the regions being looked at were
often smaller than the beam diameter. However, we appear to be seeing a mixture of Fe(II) and
Fe(III) oxidation states within the vesicles. This suggests that either the cylinder is changing
oxidation states (which is consistent with the cylinder binding to the transferrin glycoprotein),
or there are other Fe containing compounds within the cell/media.
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Figure 3.19: XANES spectra of Fe ‘hot spot’ within SKOV-3 cell (blue), [Fe2L3]
4+
pellet (purple), Fe foil (red) and ferrihydrite (green); post background removal
(top) and in derivative form (bottom). 86
To further review the apparent mixture of Fe(II) and Fe(III) states being observed, linear
combination fitting of the ferrihydrite and cylinder standards as shown in Figure 3.19 has been
performed within Athena software [92]. The resulting fit is shown in Figure 3.20 below.
Figure 3.20: Standards of ferrihydrite (green) with a weighting of 1.00 and Fe
cylinder powder (purple) with a weighting of 0.374 were used in a linear com-
bination analysis (red) and fitted to the signal observed from Fe hotspot (blue).
The results of the linear combination analysis showed that the hot spot con-
tained mainly Fe(III) species, with some Fe(II). A reduced chi squared value of
0.867 was returned from this analysis.
As determined within Athena software, the linear combination was found by combining the
entire ferrihydrite standard with 0.374 of the powdered cylinder sample. This shows that the
hotspots are predominantly Fe(III), but around a quarter (27.2%) of the iron found within this
region is Fe(II). A reduced chi squared value of 0.867 was returned from this analysis (as deter-
mined within Athena software), showing a good fit of the data. As part of the linear combination
process, the standard of iron foil was included within the list of standards with which Athena
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should perform the linear combination, but the closest fit to our sample was found to not contain
any contribution from the iron foil standard.
Following on from this, SKOV-3 cells also treated with iron cylinder but grown on quartz
were imaged, the resulting images are shown in Figure 3.21.
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(a) Optical image (b) Fe map
(c) Ca map (d) Cl map
(e) Cu map (f) K map
(g) Ni map (h) Zn map
Figure 3.21: Elemental maps and optical image of SKOV-3 cells grown on
quartz following FBS coating, and then treated with [Fe2L3]
4+ cylinder. Scale bar
represents 10 µm, intensity bar represents detected fluorescence photon count
rate. The gating of all detected fluorescence to each element was performed by
Dr Tina Geraki of Diamond Light Source.
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As with the samples grown on silicon nitride, there is a noticeable increase in iron levels
within the cell following treatment with iron cylinder. Once again, the elemental map for iron
is presented in a logarithmic scale for clarity and an iron ‘hot spot’ can again be seen close to
the cell membrane. XANES scans again showed that this area contained a mixture of Fe(II)
and Fe(III) compounds as had been seen in the cells grown on silicon nitride. It was therefore
concluded that the growth substrate used has no discernible e↵ect on the uptake of the iron
cylinder into SKOV-3 cells.
During XANES scan acquisition, it was noted that the long dwell time on any particular point
within a cell had a detrimental e↵ect on the cell’s integrity, as is shown in Figure 3.22. For the
planning of future work using this technique, this observation implies that it may not be possible
to collect XANES spectra of multiple regions of the same cell without questioning the validity
of the later acquisitions.
Figure 3.22: Optical image of SKOV-3 cell shown in Figure 3.21 following ac-
quisition of XANES spectra
Cells treated with nickel cylinder were imaged to compare localisation of this compound with
that of the iron cylinder. The images acquired are shown in Figure 3.23. Note the optical image
presented was acquired after elemental maps were acquired, and unfortunately the sample had
been damaged by ice build up on the detector. The location of the cells can however be seen
within the ice damage.
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(a) Optical image (b) Ni map
(c) Ca map (d) Fe map
(e) Cu map (f) K map
(g) Zn map (h) Cl map
Figure 3.23: Elemental maps and optical image of SKOV-3 cells grown on
quartz following FBS coating, and then treated with [Ni2L3]
4+ cylinder. Scale bar
represents 10 µm, intensity bar represents detected fluorescence photon count
rate. The gating of all detected fluorescence to each element was performed by
Dr Tina Geraki of Diamond Light Source.
It is immediately noticeable that there is an uptake of nickel into the cells when compared
with the control image shown in Figure 3.17(h). The nickel is shown to be co-localised with
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the calcium and potassium, suggesting it is taken into the centre of the cell. What is interesting
to note it that there is no sign of a nickel ‘hot spot’ at the cell membrane as there was for iron
in the cells treated with iron cylinder. Whilst this on its own is not conclusive evidence that the
cylinders are taken into the cells by di↵erent pathways, it is an intriguing result and repetition of
these experiments as a time course study may reveal if the nickel localises at the cell membrane
before being taken into the cell, and if the iron ‘hot spot’ seen eventually spreads in the cell
cytoplasm or remains at the membrane.
XANES spectra of the nickel found within the cell were recorded and again compared to
standards of nickel foil and a pellet of nickel cylinder, as shown in Figure 3.24. Spectra from
two di↵erent cells were recorded and shown to be identical to each other, and very similar to
the spectrum of nickel foil. The shoulder seen on the spectrum for powdered cylinder however
is not seen in any of the other spectra, suggesting the nickel found in the cell is not in the same
environment as the nickel at the centre of the cylinder.
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Figure 3.24: XANES spectra of Ni containing area within SKOV-3 cell (blue and
purple), [Ni2L3]
4+ pellet (red), and Ni foil (green); post background removal (top)
and in derivative form (bottom).
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Attempts were also made to image ruthenium cylinder within MDA-MB-231 cells. This
however proved di cult to perform due to the hardware available on I18 beamline. The K edge
of ruthenium is 22117 eV, which is above the energy range obtainable at I18, where optics and
wigglers are set up to focus the beam to lower energies to cover edges more commonly studied.
The L1 and L2 edges of ruthenium have been detected at 3224 eV and 2967 eV respectively
whilst the L3 edge at 2838 eV [93]. Unfortunately, the L3 edge is unresolvable from the chlorine
K edge found at 2822 eV [94], and the L1 and L2 edges are only seen at much lower intensities so
would be very di cult to confidently assign within a spectrum. A spectral subtraction process
was undertaken to try and isolate a map due to ruthenium L3 edge, but this was unsuccessful. It
was therefore decided that work should concentrate on determining the cellular localisation of
iron and nickel based cylinders.
3.4.8 Initial conclusions on data acquired
These initial attempts at cellular imaging of cylinders have led to the development of a suit-
able protocol for cell growth on silicon nitride windows and quartz slides. Treatment with iron
cylinder has been shown to lead to ‘hot spots’ of iron at the membrane as well as within the cells,
whereas nickel cylinder treatment leads only to nickel spread throughout the cell. It however is
noted that due to damage to the samples during acquisition, a complete set of data of control,
iron cylinder treated and nickel cylinder treated cells all grown on the same substrate could
not be collected during the synchrotron beam-time allocated to this project to date. Any future
beam-time access will be used (in combination with the experience gained from experiments
performed here) to obtain this complete data for multiple cell lines.
Work so far has also shown how information about the oxidation state of metals found within
cells can be investigated using XANES spectroscopy. However future experiments must be
designed carefully to ensure that multiple XANES scans are not required from one cell due to
the damage caused by spectrum acquisition.
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Chapter 4
Investigating the e↵ect of cylinder on cells
4.1 Investigating cells morphology and motility
It is not enough to just determine the cellular localisation of the cylinder compounds - their
e↵ects on cells must also be investigated to determine their full cause of toxicity. These e↵ects
can include cell morphology, motility and surface adhesion which can all be observed readily
using microscopy techniques. Therefore phase contrast and fluorescence confocal microscopy
have been used to observe the e↵ects of cylinder treatment on two principle cell lines; MDA-
MB-231 and SKOV-3.
4.1.1 Phase contrast imaging of MDA-MB-231 and SKOV-3 cells
Previous work within the group had begun investigating the e↵ects of [Fe2L3]
4+ on the motility
of MDA-MB-231 cells [14]. That work showed that [Fe2L3]
4+ caused changes in cell morphol-
ogy even at time points where [Fe2L3]
4+ is known to be non-lethal.
To build on and expand this work, the e↵ects of iron cylinder on the morphology and motility
of MDA-MB-231 cells has been investigated using time-lapse phase contrast microscopy. Four
analogues of the iron cylinder were synthesised to investigate the e↵ect of changing the central
CH2 moiety of the ligand for hetero atoms such as oxygen ([Fe2L
O
3]
4+) or sulphur ([Fe2L
S
3]
4+),
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and also the e↵ect of introducing a methyl group in place of the imine hydrogen ([Fe2L
Me
3]
4+).
The structures of these ligands are shown in Figure 4.1.
Figure 4.1: Structures of cylinder ligands, (from top to bottom) parent ligand (L),
oxygen ligand (LO), sulphur ligand (LS) and methyl ligand (LMe).
[Fe2L
S
3]
4+ and [Fe2L
O
3]
4+ have already been shown to bind to DNA 3-way junctions, but the
[Fe2L
O
3]
4+/DNA complex shows reduced thermal stability [95]. [Fe2L
Me
3]
4+ however, has very
di↵erent DNA binding results. Gel electrophoresis studies appear to suggest that less than 10%
of the DNA is found in a three-way structure when treated with [Fe2L
Me
3]
4+ compared with over
40% of DNA found when treated with [Fe2L3]
4+. Toxicology studies also show that [Fe2L
Me
3]
4+
is inactive to concentrations up to 100 µM in A2780 ovarian cancer and MDA-MB-231 cells.
This is in stark contrast to [Fe2L3]
4+ which shows toxicity comparable to cisplatin [14]. These
results suggest a direct correlation between cylinder binding to three-way junction and cylinder
toxicity.
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Cells were seeded into 6-well plates, allowed to adhere for 24 hours before being treated
with 100 µM of compound. The plate was then imaged using a phase contrast microscope with
a heated stage and controlled CO2 environment: Images were acquired every 5 minutes. From
the videos obtained, it is apparent that addition of any of the compounds leads to an almost
complete arrest in cell movement. Stills from the videos at t=zero, one, two, three and four
hours are shown in Figure 4.2 to Figure 4.6. Over the 4 hours of the experiment, there are no
obvious signs of cell death such as breakdown of the membrane or the cells detaching from the
surface, so it is believed that the cylinder is having a specific e↵ect on the cell motility, either
by interaction with the cell cytoskeleton or by interrupting the signalling cascade. In the cells
treated with [Fe2L3]
4+, the viability of the cells was confirmed by the observation of almost
complete cell replication, wherein replication of the nucleus can clearly be observed but the
two daughter cells seem to be incapable of separating. Two leading edges are formed, and the
cells attempt to move in opposite directions but instead of separating, a long, thin spindle is
formed between the two cells which ends in both cells suddenly moving back to their starting
point. This was not observed in cells treated with the other three cylinders, but these seem to
completely arrest the movement of some cells, with the cells observed at t=0 hour still in the
field of view at t=4 hour, particularly for the cells treated with [Fe2L
O
3]
4+. In contrast however,
the cells treated with [Fe2L
Me
3]
4+ do not show such a decrease in motility. This nicely correlates
with the toxicity data, as the one cylinder we know does not bind to the DNA three-way junction
and shows no toxicity at concentrations below 100 µM does not appear to have any e↵ect of cell
motility.
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Figure 4.2: Time lapse images of untreated MDA-MB-231 cells, imaged over 4
hours. Clear movement of the cells is observed in between each frame.
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Figure 4.3: Time lapse images of MDA-MB-231 cells treated with 100 µM
[Fe2L3]
4+, imaged over 4 hours. Little movement of cells is seen in between
each frame. 99
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Figure 4.4: Time lapse images of MDA-MB-231 cells treated with 100 µM
[Fe2L
Me
3]
4+, imaged over 4 hours. No real arrest of movement was noted in
these images, with cell division seen to be occurring.100
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Figure 4.5: Time lapse images of MDA-MB-231 cells treated with 100 µM
[Fe2L
O
3]
4+, imaged over 4 hours. After one hour, very little movement of cells is
observed. 101
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Figure 4.6: Time lapse images of MDA-MB-231 cells treated with 100 µM
[Fe2L
S
3]
4+, imaged over 4 hours.
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This work was repeated with SKOV-3 ovarian cells to see if the cylinders arrested cell move-
ment in a second cell line. Control images of untreated cells and cells treated with cisplatin
were recorded and are presented in Figure 4.7 and Figure 4.8 respectively.
(a)
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hour
(b)
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hours
(c)
Three
hours
(d)
Four
hours
Figure 4.7: Time lapse images of untreated SKOV-3 cells, imaged over 4 hours.
There is clear movement of the cells in between each frame.
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Figure 4.8: Time lapse images of SKOV-3 cells treated with 100 µM cisplatin
(bottom row), imaged over 4 hours. By four hours, many of the cells appear to
have entered apoptosis as they become spherical and begin to detach from the
surface.
The untreated cells are seen in a large monolayer, and move freely within this. Cells treated
with cisplatin initially remain moving within their monolayer before contracting, finally appear-
ing to completely ‘ball up’. Imaging of cells treated with the four iron cylinders are presented
in Figures 4.9 to 4.12.
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Figure 4.9: Time lapse images of SKOV-3 cells treated with 100 µM [Fe2L3]
4+,
imaged over 4 hours. Little movement of cells is observed.
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Figure 4.10: Time lapse images of cells treated with 100 µM [Fe2L
Me
3]
4+, im-
aged over 4 hours. Little movement of cells is observed.
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Figure 4.11: Time lapse images of cells treated with 100 µM [Fe2L
O
3]
4+, imaged
over 4 hours. Increasing cellular debris is noted, but a layer of cells with reduced
movement are visible beneath.
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Figure 4.12: Time lapse images of cells treated with 100 µM [Fe2L
S
3]
4+, im-
aged over 4 hours. A complete arrest of movement is observed, with increasing
cellular debris.
Once again, it was seen that there was a decrease in cellular movement following cylinder
treatment. SKOV-3 cells treated with [Fe2L3]
4+, [Fe2L
O
3]
4+ and [Fe2L
S
3]
4+ showed similar re-
sults to MDA-MB-231 cells when treated with these compounds - within 2 hours post treatment
cell movement is almost completely arrested. Surprisingly, this decrease in cell movement is
also seen following treatment with [Fe2L
Me
3]
4+, the opposite of what is seen in MDA-MB-231
cells treated with this compound. It is not known what would cause this di↵erence in e↵ect,
as it is known that [Fe2L
Me
3]
4+ does not bind to DNA [14]. This result does however point to
a explanation that all of the e↵ects on cell motility (across both cell lines) are caused by an
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interruption to the signalling cascade, not by direct binding to DNA.
4.1.2 Imaging cell actin structure with Lifeact-GFP
As the motility and morphology of cells are clearly a↵ected by treatment with our cylinder
compounds, work began to image the cell cytoskeleton, and particularly the protein actin. Actin
is a globular protein found in all eukaryotic cells. It polymerises into a fibrous form, known
as F-actin, which not only forms the thin filaments of muscle, but also the microfilaments that
constitute part of the cell cytoskeleton. Previous work within the group has suggested that
the cylinder may interfere with the F-actin structure of MDA-MB-231 cells [14]. Treatment
of the cells with 50, 100 and 200 µM cylinder appeared to show ’ru✏ing’ of the cells’ actin
filaments with increasing cylinder concentration, shown in Figure 4.13. This was visualised
by the staining of actin using a commercially available dye - FITC-phalloidin. The phalloidin
moiety is known to bind to branches of F-actin, whilst FITC acts as a fluorophore ( ex = 496nm,
 em = 518nm). Phalloidin can also be combined with other fluorophores such as rhodamine
( ex = 557nm,  em = 577nm), making the imaging of the co-localisation of actin with other
fluorophores (such as [Ru2L3]
4+) an attractive option.
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(a) Control image
(b) Image following treatment with 200uM cylinder
Figure 4.13: Images of MDA-MB-231 cells stained with FITC-phalloidin; control
image and image of cell treated with 200 µM parent cylinder [14]
Whilst staining with phalloidin is a very reliable way of imaging actin, the cellular membrane
needs to be disrupted in order for the compound to be taken up, and therefore can only be
performed on fixed cells. As we were hoping to study the e↵ects of our cylinder over time, it
was felt important to keep the membrane uncompromised to prevent unrealistic uptake of the
cylinder. It was therefore decided to utilise the recently developed Lifeact marker [96]. This is
a simple 17 amino acid peptide which is highly conserved in Saccharomyces cerevisiae yeast.
Lifeact can be fused to green fluorescent protein (Lifeact-GFP) ( ex = 488nm,  em = 509nm) and
introduced to cells as part of a vector plasmid which can be taken into cells without damaging
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the cell membrane. Lifeact-GFP has been shown to stain actin without interfering in cellular
processes, and the considerable di↵erence in emission maxima of GFP and our cylinder should
allow for the co-localisation of the two fluorophores to be determined. Furthermore, as there is
reported work showing that NAMI-A causes HeLa cells to contract and leave their lamellopodia
actin-free [97], it would be interesting to see if the ruthenium cylinder had a similar e↵ect.
In collaboration with Dr Steve Thomas (IBR, Birmingham), the Lifeact vector was ex-
pressed in E. coli bacteria cells and then isolated using a Sigma Aldrich Genelute Maxiprep
Kit, ready to be introduced into our cells.
4.1.3 Fluorescence imaging of MDA-MD-231 actin structure
At the time of this work there were no literature reported example of Lifeact-GFP transfected
MDA-MB-231 cells, however there was an several example of MBA-MB-231 cells transfected
with Lifeact-mCh [98]; Lifeact fused to mCherry fluorescent protein, so this was used as the
starting point for our transfection protocol. The experimental detail provided in this paper de-
scribes a simple transfection experiment, using commercially available cationic lipid transfec-
tion reagents. The use of all cationic lipid transfection reagents follow a very similar protocol
where the DNA plasmid of interest is incubated in the transfection reagent and serum-free me-
dia. This allows the cationic lipid to interact with the phosphate backbone of the DNA, forming
a DNA:liposome complex which can then be combined with serum containing media and used
to treat cells. If the DNA:liposome complex has successfully formed, then it should be endo-
cytosed into the cells where the liposome breaks down leading to release of the DNA plasmid
into the cytoplasm where it can be expressed. The absence of serum in the first step is crucial to
ensuring the formation of the DNA:liposome complex. Control images of MDA-MB-231 cells
transfected with Lifeact-GFP, but not treated with ruthenium cylinder show that the cells have
retained their characteristic ‘spindle-like’ morphology and are clearly expressing GFP, shown
in Figure 4.14.
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Figure 4.14: MDA-MB-231 cells transfected with Lifeact-GFP, brightfield image
(left) and corresponding fluorescence image (right).
As the transfection appeared to have been successful,the cells were treated with varying con-
centrations of [Ru2L3]
4+ and imaged using fluorescence confocal microscopy. A control sample
of cells treated with cytochalasin D, a compound known to depolymerise actin fibres, was also
prepared. A change in morphology of the cells is observed with increasing [Ru2L3]
4+, as shown
in Figure 4.15.
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Figure 4.15: MDA-MB-231 cells transfected with Lifeact-GFP, and increasing
concentrations of [Ru2L3]
4+. From left to right; fluorescence between 500-
520nm, fluorescence between 680-720nm,and brightfield image. From top to
bottom, concentration of [Ru2L3]
4+; control, 10 µM, 20 µM, 50 µM
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By 50 µM concentration of [Ru2L3]
4+, the cells appear more spherical two cells in the centre
of those images appear very similar in appearance to the cells treated with cytochalasin D,
shown in Figure 4.16. As GFP is excited using the 488nm laser, fluorescence images in the
680-720nm range were also collected to observe any cylinder fluorescence. Again in the 50
µM sample, cylinder associated fluorescence can clearly be seen in all areas of the cell. It is
however not seen in high intensity in the regions of high intensity GFP fluorescence suggesting
the GFP and cylinder are not co-localised.
Figure 4.16: MDA-MB-231 cells transfected with Lifeact-GFP and then treated
with cytochalasin D - fluorescence recorded between 500-520nm (left) and
brightfield image (right).
Attempts to repeat the transfection were less successful, with possible precipitation of
Lifeact-GFP observed around the nucleus. Modifications to the protocol centred on increasing
DNA:liposome complex incubation time from 24 to 72 hours, and when this did not completely
solve the problem, attention turned to maintaining a population of transfected cells, instead of
repeating small scale transfections before each experiment. Cells survived comfortably for a
week post transfection, applying normal cell cultures protocols. These changes improved the
overall labelling, as structures such as the microtubule organisation centre (MTOC) and the
leading edge of a moving cell can now be observed, and are shown in Figure 4.17. How-
ever, whilst the viability of the cells was not compromised, the number of cells expressing
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Lifeact-GFP decreased, meaning the DNA plasmid was either being degraded, or was not be-
ing replicated during cell division, meaning the proportion of cells expressing the Lifeact-GFP
will decrease by 50% with each cell replication cycle. Work therefore began on improving the
transfection protocol, firstly by using antibiotic selection to preserve the stably transfected cells
and secondly by investigating the technique of electroporation to deliver the plasmid directly to
the nucleus, which may lead to more e cient expression of the plasmid.
Figure 4.17: MDA-MB-231 cells transfected with Lifeact-GFP, brightfield
and corresponding fluorescence images 5 (top) and 7 days (bottom) post-
transfection.
Electroporation allows a plasmid to cross the cell membrane by increasing its permeability
due to the application of an electrical field. This electrical field also temporarily disrupts the
membrane of the nuclear envelope, meaning the plasmid can directly enter the nucleus. For the
first attempts at nucleofection, a simple max-GFP plasmid was used in order to preserve Lifeact-
GFP plasmid for future experiments. The electroporation was performed using an Axama Nu-
cleofector (Lonza) using program X-013, which was recommended for the MDA-MB-231 cell
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line. However, initial experiments all resulted in immediate cell death. Attempts using di↵erent
programs, di↵erent electroporation reagents and varying concentrations of cells and plasmid all
also resulted in immediate cell death. At this point, it was decided to leave electroporation ex-
periments and return to improving the transfection protcol, again using the maxGFP plasmid for
initial studies. As well as repeating work with Turbofect, three other commercially available
transfection reagents were trialled; X-tremeGENE 9 (Roche), TransIT 293 and TransIT LT-1
(both Mirus). Images were acquired 24 and 48 hours post-transfection, which showed that all
four reagents had lead to some transfection of the plasmid, but the sample treated with Turbofect
contained a much larger number of fluorescent cells so it was decided to continue work with
this reagent. The images acquired at 24 and 48 hours are shown in Figure 4.18 and Figure 4.19
respectively.
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(a) Brightfield (b) Fluorescence (c) Overlay
(d) Brightfield (e) Fluorescence (f) Overlay
(g) Brightfield (h) Fluorescence (i) Overlay
(j) Brightfield (k) Fluorescence (l) Overlay
Figure 4.18: MDA-MB-231 cells transfected with maxGFP, using a different
transfection reagent for each row; TransIT293 (top), TransITLt1 (second row),
Turbofect (third row), X-tremeGENE 9 (bottom). Each row shows brightfield im-
age (left), fluorescence above 500nm following excitation at 488nm (middle),
and the overlay of these images (right). All images recorded 24hrs post trans-
fection. All images at 100x magnification.
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(a) Brightfield (b) Fluorescence (c) Overlay
(d) Brightfield (e) Fluorescence (f) Overlay
(g) Brightfield (h) Fluorescence (i) Overlay
(j) Brightfield (k) Fluorescence (l) Overlay
Figure 4.19: MDA-MB-231 cells transfected with maxGFP, using a different
transfection reagent for each row; TransIT293 (top), TransITLt1 (second row),
Turbofect (third row), X-tremeGENE 9 (bottom). Each row shows brightfield im-
age (left), fluorescence above 500nm following excitation at 488nm (middle),
and the overlay of these images (right). All images recorded 48hrs post trans-
fection. All images at 100x magnification.
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A further transfection experiment was performed using Turbofect transfection reagent. Af-
ter 48 hours, the cells were placed into a T25 flask and grown in media containing the antibiotic
G418. The plasmid used to transfect the cells with Lifeact-GFP also contained the genetic code
for G418 resistance, so growing cells in these conditions should allow only successfully trans-
fected cells to survive leading to a large population of cells expressing Lifeact-GFP. Initially the
media was dosed with a low concentration of G418, with the aim of increasing its concentration
over 2-3 weeks. However, even at low doses, the antibiotic killed almost all the cells and those
that did survive did not replicate (even when switched back into G418-free media), meaning
the whole population died within 5-7 days. Repeated attempts at producing a stable population
failed, so it was decided to revert to performing transfections on a small sample of cells as and
when required. Since this work was performed, the first paper has been published with Lifeact-
GFP transfected MDA-MB-231 cells [99]. This work describes the transient transfection of
cells using a further transfection reagent - Lipofectamine 2000 (Invitrogen), which may be an
avenue to investigate for future work.
To conclude this section of work, a final experiment was performed using MDA-MB-231
cells transiently transfected with Lifeact-GFP. The cells were treated with [Fe2L3]
4+ for two,
four or six hours, fixed and imaged using fluorescence confocal microscopy. It is known that
[Fe2L3]
4+ can quench the fluorescence of GFP [76], so if [Fe2L3]
4+ co-localises with the Lifeact-
GFP, a decrease in fluorescence intensity should be observed with increasing treatment time.
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(a) control fluorescence (b) control brightfield
(c) 2hrs fluoresence (d) 2hrs brightfield
(e) 4hrs fluorescence (f) 4hrs brightfield
(g) 6hrs fluorescence (h) 6hrs brightfield
Figure 4.20: MDA-MB-231 cells transfected with Lifeact-GFP and treated with
[Fe2L3]
4+ for two, four or six hours showing clear change in cell morphology.
120
After just two hours treatment, a change in the cell morphology is clear - the cells are no
longer thin and spindle-like, they have spread out and show leading edges along their entire
length, which is uncharacteristic for this cell line. By four hours the cells have continued to lose
their characteristic morphology and more large leading edges are visible. Following six hours
treatment, the cells are almost unrecognisable from the control images. The clear labelling of
the actin structure at two and four hours treatment however suggests that the Lifeact-GFP is
not being quenched by [Fe2L3]
4+ and, as believed with [Ru2L3]
4+, the cylinder does not directly
bind to the actin subskeleton of MDA-MB-231 cells.
Following on from the phase contrast imaging shown in Figure 4.4, the one cylinder which
did not cause any decrease in cell motility was [Fe2L
Me
3]
4+. Therefore Lifeact-transfected
MDA-MB-231 cells were treated with [Fe2L
Me
3]
4+, and imaged as above. The images obtained
are shown in Figure 4.21.
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(a) 4hrs fluorescence (b) 4hrs brightfield
(c) 6hrs fluorescence (d) 6hrs brightfield
Figure 4.21: MDA-MB-231 cells transfected with Lifeact-GFP and treated with
[Fe2L
Me
3]
4+ for four or six hours showing no change in cell morphology following
cellular treatment.
These images confirm that the structural integrity of the cells is maintained following treat-
ment [Fe2L
Me
3]
4+, which again suggest that there is no direct interaction between the cylinders
and actin. The branched nature of actin means that there are many junctions of varying sizes
that any compound could bind to. Whilst the methyl groups on [Fe2L
Me
3]
4+ prevent its binding
to the DNA Y-shaped junction, it seems unlikely that these groups could prevent binding to the
larger junctions of the actin protein. As the only disruption to cellular structure and motility
is seen when treated with compounds which are known to bind to DNA, it seems logical that
it is caused by an interruption of the signalling cascade and not direct interaction between the
cylinders and actin.
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4.2 Investigating the production of gaseous species within
MDA-MB-231 and SKOV-3 cells
As it is not believed that the decrease in cell motility observed following cell treatment is due
to direct interaction with actin, attention was turned to investigating if cylinder treatment lead
to the production of compounds which are known to disrupt the motility of cells. A literature
review revealed some very interesting work describing the e↵ect of nitric oxide (NO) on two
of the cell lines investigated earlier in this chapter; MDA-MB-231 and LX-2 cells, and it is
discussed in the following sections.
4.2.1 NO and its role in cell function
Nitric oxide is a small gaseous molecule intrinsic to cellular processing and signalling. As it
is involved in so many processes, there is conflicting opinion in the literature as to whether
NO could be used as part of cancer combination therapy, or if it leads to drug resistance [100]
[101] [102]. It is produced within mammalian cell lines during the conversion of L-arginine to
L-citrulline by three enzymes known as the NO synthase (NOS) family.
L arginine + 32 NADPH + H+ + 2O2   ! citrulline + NO + 32 NADP+
The three isoforms of NOS are traditionally named after the cell type in which there were first
isolated [103]. nNOS was first isolated from neuronal tissue, but is predominantly found in
skeletal tissue. iNOS was first found in macrophages and so was termed ‘inducible NOS’. The
third isoform to be isolated, eNOS, was derived from endothelial cells but is found in platelets
and the hippocampus. To further confuse matters, eNOS is additionally termed constitutive
NOS (cNOS). To ease confusion, the NOS family are o cially categorised as NOS1 (nNOS),
NOS2 (iNOS) and NOS3 (eNOS and cNOS), and this terminology will be used from here
onwards.
Looking specifically at MDA-MB-231 cells, it has previously been stated that these cells do
not produce NO endogenously [104]. This statement was based on the work of Zeillinger et al
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who stated that DNA that codes for NOS3 was not detectable in MDA-MB-231 cells using cRT-
PCR [105]. Subsequent papers by Pervin et al have repeated Zeillinger’s findings and showed
that neither NOS3 nor NOS2 are detectable by cRT-PCR [106]. This is however contradictory
to the work of Mathews et al who used Western Blot experiments to show that MDA-MB-
231 cells contain all three isoforms of NOS [107] and treatment with specific NOS3 inhibitor
N-LIO increased cell motility[108], again suggesting that MDA-MB-231 cells do contain the
NOS isoforms.
NO pro-drug NONO-AM has been shown to be toxic to MDA-MB-231 cells, with NO being
released from the drug by esterase enzymes. Cell death correlated with increasing NO levels
within cells [109]. Work by Lahiri and Martin investigated the e↵ect of NO on the adhesion
and motility of MDA-MB-231 cells [108]. This work again showed a ‘two-sided’ nature of
NO. Low levels of NO (introduced into the cells by treating them with 5 mM L-arginine) were
shown to decrease motility as determined by scratch-wound assay, but higher levels of NO
decreased cell adhesion. The reported e↵ects of NO upon on MDA-MB-231 cells are similar
to the e↵ects observed following cylinder treatment, suggesting that the changes in cell motility
seen following cylinder treatment may be due to the production of NO.
4.2.2 Investigating the production of NO within cells
Whilst there are many reported probes for NO [110] [111] [112], they are almost all compro-
mised by their non-specificity towards NO, and the fact they contain fluorescent groups such
a fluoroscein. A recently published, and now commercially available probe however seems to
overcome the disadvantages of the traditional NO probes [15]. This probe, NO550, does not
contain a diaminobenzene moiety, the electron rich and highly reactive group which reduced
the specificity of previous NO probes. In the presence of NO and O2, NO550 enters a cascade
reaction to form a diazo compound, AZO550, the mechanism for which is shown in Figure 4.22.
Upon excitation with 470nm light, AZO550 has emission centred at 550nm. NO550 shows no
such emission following excitation at 470nm, and treatment of NO550 with molecules such as
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H2O2, ONOO
– and DHA (all of which are known to interfere with currently used probes) does
not lead to the formation of AZO550, or any other fluorescent compound. This demonstrates the
selectivity of NO550, and combined with its pH stability and previous use in imaging endoge-
nous NO [15], this made it an extremely attractive route for investigating NO production within
the cell lines previously imaged.
Figure 4.22: Mechanism of AZO550 production from NO550 [15]
The first step was to establish the toxicity of NO550 towards MDA-MB-231 cells, so the MTT
assay was used to determine an IC50 for NO550. The NO550 shows poor solubility in media
which may explain the large error values associated with each concentration value. A Student’s
T-test comparing the control samples and those treated at 100 µM using a p=0.05 significance,
found that there was no significant di↵erence between the two populations, so it was determined
that NO550 was not toxic to cells over 72 hours at the concentrations tested.
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Figure 4.23: MTT data of NO550 probe, showing that the probe is non-toxic to
MDA-MB-231 cells. Plot shows mean and standard deviation (n=3) of triplicate
experiments, each experiment was performed in quadruplicate. A Student’s t-
test was performed using p=0.05, which showed that there was no statistically
significant difference in growth rates between populations treated with NO550
probe, and those populations which were left untreated.
To investigate the e↵ect of the iron cylinder on NO production within MDA-MB-231 cells,
they were incubated with 100 µM of iron cylinder 4h, followed by a 20 minute incubation
with 50 µM NO550 probe. The cells were then fixed and mounted before being imaged using
fluorescence confocal microscopy. Control samples of NO550 probe alone and FeCl2, parent
ligand and Ru(NO3)3NO with NO550 were also prepared. The ruthenium nitrosyl sample was
prepared as positive control as a source on NO, it was expected that cells treated with NO550
followed by ruthenium nitrosyl would lead to the observation of an fluorescent signal within
the cell. The images produced show that control sample of cells alone, when excited at 488nm
show no autofluorescence in the 520-560nm region. The sample containing just NO550 probe,
shows low levels of fluorescence in the 520-560nm region, showing that MDA-MB-231 cells do
contain low levels of endogenous NO. The sample treated with ruthenium nitrosyl shows large
amounts of fluorescence showing that the probe does indeed work in cells with a source of NO.
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Excitingly, the sample treated with [Fe2L3]
4+ also shows high levels of fluorescence - strongly
suggesting that the parent cylinder induces the production of NO within MDA-MB-231 cells.
As control samples containing just FeCl2 or parent ligand resulted in low levels of fluorescence
being observed, the e↵ect observed following treatment with [Fe2L3]
4+ is not as a result of the
cylinder being metabolised into starting materials either in media or within the cells. All images
are shown in Figure 4.24.
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(a) control fluorescence (b) control brightfield
(c) Ru(NO3)3NO fluorescence (d) Ru(NO3)3NO brightfield
(e) [Fe2L3]
4+ fluorescence (f) [Fe2L3]
4+ brightfield
Figure 4.24: Fluorescence and brightfield images of MDA-MB-231 cells show-
ing images of cells treated with; (a-b) no compounds (c-d) Ru(NO3)3NO with
NO550 and (e-f) [Fe2L3]
4+ with NO550.
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The samples were re-imaged using an integrated microscope-spectrophotometer system to
record images and emission spectra for each sample, to hopefully show the presence of an
emission band between 520-560nm in samples we believe contain NO. This however proved
unsuccessful, as no emission peak in the 520-560nm range could be observed. This was believed
to be due to the AZO550 photobleaching over the 8 minutes required to record each spectrum.
Attention therefore turned to trying to quantify the amount of fluorescence produced by each
compound. This was done by determining the mean pixel intensity for each image, using the
same algorithm described in Section 3.3.1, and the resulting calculated average intensities are
presented in Figure 4.25.
129
Figure 4.25: Intensities of thresholded images containing NO550 probe, showing
cells treated with Ru(NO3)3NO or [Fe2L3]
4+ lead to significantly increased fluo-
rescence signal compared to control samples. Mean pixel intensity shown with
one standard deviation (n=3). A Student’s t-test at p=0.05 showed that there
is a statistically significant difference between the average fluorescence from
samples treated with Ru(NO3)3NO or [Fe2L3]
4+ compared to all other samples.
These intensities show that the levels of fluorescence seen in samples treated with Fe cylinder
or Ru(NO3)3NO are significantly higher than those seen in samples treated with ligand, FeCl2
or NO550 probe alone (as supported by use of Student’s t-test) - strongly suggesting the presence
of cylinder induces the production of NO within MDA-MB-231 cells.
Whilst these images are not conclusive that the production of NO is the cause for the change
in cell motility, they do show an interesting property of the cylinder that was previously un-
130
known and open up the potential for a entirely new line of work to fully determine the cylin-
der’s mode of action. Repeating this work with [Fe2L
Me
3]
4+, which did not appear to have any
e↵ect on cellular motility would allow for a more definitive conclusion to be drawn - if no NO
is produced following treatment with [Fe2L
Me
3]
4+, it could then be said that the NO is the cause
of the decreased motility.
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Chapter 5
Towards developing a MALDI imaging
protocol for imaging cylinder within tissue
5.1 Mass Spectrometry and its application to imaging biolog-
ical samples
Light microscopy has provided a solid technique for imaging the cylinders and their e↵ects
upon cells. However, it does not allow for any investigation into their metabolic fate; once
metabolised the ruthenium cylinder loses its fluorescent properties and so can no longer be
detected. There is therefore a need to complement the fluorescence microscopy studies pre-
sented here with a technique which provides chemical information about the metabolic fate of
the ruthenium cylinder, such as mass spectrometry (MS). Fluorescence microscopy studies pre-
sented in Section 3.2.1 can show the fate of ruthenium cylinder where the Ru N6 chromophore
remains intact, but would not show the localisation of any ruthenium not bound within the cylin-
der. The XRF studies presented in Section 3.4.4 can show the localisation of elements within
a cell, but it cannot be used to determine which compound those elements are found in. By
using MS, it is possible to obtain chemical information that can then be used to identify the
coumpounds present. The basic events of MS are ionisation of the sample, separation of these
ions on the basis of their mass to charge (m/z) ratio, and then the detection of these ions. A
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final spectrum is produced displaying the number of ions of each m/z ratio and it is then for the
user to determine which chemical species each m/z ratio corresponds to. MS has been shown to
be applicable in a significant range of sample material, from small molecular weight molecules
through to large peptides and proteins, determining parameters as varied as elemental composi-
tion through to the detection of lipids in brain tissue samples. This is only possible due to the
development of a wide range of ionisation techniques.
The ultimate hard ionisation technique is Inductively Coupled Plasma MS (ICP-MS). The
sample is introduced to an argon plasma as an aerosol produced by either laser ablation of
a solid sample or by passing a liquid sample through a pneumatic nebuliser. The sample is
then vaporised, atomised and ionised. In this extreme environment, only elemental ions will
be formed - no intact molecules of the initial sample will remain. This means that whilst the
elemental composition of the sample can be determined, no information can be gathered about
the sample’s chemical composition. The energy within the plasma is around 15.8eV (the first
ionisation energy of argon) which allows for ionisation of nearly all the elements of the periodic
table as the majority of elements ionise between 4-12eV. The potential for multi-element de-
tection with sensitivity in the parts per billion (ppb) range (depending upon the element) makes
ICP-MS one of the most utilised trace element detection techniques. A recent study showed
that LA-ICP-MS was a complementary technique to MRI imaging with improved sensitivity
and access to information about the fate of carboplatin within pig brain [113].
Secondary Ion Mass Spectrometry (SIMS) also allows for the elemental composition of a
sample to be determined, but does not use a laser to ionise the sample. An ion gun within the
instrument produces a beam of positive (normally Cs+) or negative (normally O2–) ions which
are termed the ’primary ions’. These ions are focused onto the sample leading to the sputtering
of sample ions which are then termed as the ’secondary ions’ which give this technique its
name. This ionisation method is not as e cient as ICP-MS, as for every one charged species
produced, there are 10,000 neutral species released from the sample which cannot be detected
by MS, and there are also issues surrounding sample preparation which can include the need to
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sputter coat the sample with gold to improve the conductivity of the surface. Whilst these issues
are clearly disadvantages with SIMS, the technique has found applicability in analysing small
molecules following the development polyatomic primary ion beams such as gold clusters [114]
or buckminsterfullerene ions [115].
The technique of SIMS only allows for ionisation of small molecules, larger molecules such
as peptides and proteins will fragment under these conditions. Nobel Prize winning chemistry
carried out in parallel by two separate research groups led to the development of Matrix Assisted
Laser Desorption Ionisation MS (MALDI-MS) [116] [117]. By co-crystallising the sample with
a large molar excess of a matrix, the sample is protected from the full force of a laser, resulting
in predominantly singularly charged intact sample ions. This technique has been shown to be
applicable to samples as large as 1 million Da. As a second material is being introduced to the
sample to be analysed, it is imperative that the matrix chosen does not alter the composition of
the sample. Matrices are generally small organic molecules which must be chosen to e ciently
absorb the light emitted by the instrument laser. As the most commonly used lasers are nitrogen
lasers emitting at 337nm, four of the most commonly used matrices - ↵CHCA, THAP, DHB
and SPA (shown in Figure 5.1) - are compounds which all readily absorb UV light. The choice
of matrix, as well as the method of matrix application (by techniques such as airbrushing, elec-
trospray or acoustic droplet spotting) is not governed by a well-defined set of rules - the events
involved in the co-crystallisation of sample and matrix are not wholly understood and so the
optimum sample preparation protocol must be determined for each new sample.
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Figure 5.1: Structures of four commonly used matrices in MALDI-MS; a) a-
hydroxy-4-cinamic acid (↵CHCA), b) sinapinic acid (SPA), c) 2,5-dihydroxy-
benzoic acid (DHB) and d) 2’,4’,6’-trihydroxy-acetophenone (THAP).
LA-ICP-MS, SIMS and MALDI-MS all allow for imaging of their samples. This is achieved
by recording mass spectra at thousands of discrete locations within the sample and then using
these to produce images showing the ion counts of the desiredm/z ratio at each location, in much
the same way as elemental maps are produced using XRF as previously discussed in 3.4.1. A
schematic of MS imaging is shown in Figure 5.2.
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Figure 5.2: Schematic of MS imaging showing how multiple m/z values of in-
terest can be imaged within one sample and one acquisition experiment. Image
reproduced with permission from Figure 1 in [16].
As MALDI-MS has the ability to ionise molecules as large as proteins, any experiment
searching for drug molecules in tissue are complicated by the presence of huge amounts of
background material as well as matrix associated peaks. Early work on using MALDI-MS to
analyse drug in tissue samples highlighted the importance of being able to conduct MS/MS
experiments, where an m/z ratio of interest can be isolated within an ion trap and subjected to
a second MS experiment. This second experiment is used to fragment this species and use the
resulting spectrum to conclusively identify the species as either being drug or naturally occur-
ring within the tissue. The Caprioli group have pioneered the use of MALDI-MS for imaging
biological samples [118] and presented images of drug distribution (shown in Figures 5.3(a)
and 5.3(b)) in tissue as far back as 2001 [17], and more recent work within other groups has
shown that the images produced by MALDI-MS are comparable with those produced by au-
toradiography studies [18], a current standard procedure in the pharmaceutical industry.
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Figure 5.3: Left - Superimposed image of optical image of rat cortex and ion
density map of clozapine (an anti-psychotic medication) obtained from the same
sample. Image reproduced with permission from Figure 4 in [17]. Right - Top;
optical image, Middle; autoradiography image and Bottom; MALDI-MS/MS im-
age of clozapine in rat brain. The MALDI MS image shows good correlation with
the autoradiogrphy image. Image reproduced with permission from Figure 6 in
[18].
Mass Spectrometry has enormous applicability for imaging drug candidates within tissues
and o↵ers the significant advantage over current procedures (such as autoradiography) that the
metabolic fate of the compound can be studied. It is hoped that these techniques will be ap-
plicable to studying our cylinders within cells and tissues. As ruthenium is not naturally found
within cells, it allows all MS imaging techniques described to be utilised - LA-ICP-MS can de-
tect ruthenium within tissue, SIMS could be used to image at sub-cellular level and MALDI-MS
could be used to detect intact molecule and metabolites within tissue samples.
5.2 Studies with cylinder on steel plates
Initial work with mass spectrometry of [Ru2L3]
4+ began with studies into determining how
suitable the cylinder is for such analysis. We must be able to observe m/z peaks that clearly
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correspond to cylinder ions or fragments (with good ion counts). Ideally we would also like
to be able to select an m/z peak we believe is a cylinder ion and subject that to an MS/MS
experiment and fragment it to produce a ’fingerprint’ spectrum which could then be used to
confirm the presence of cylinder within a given sample.
A 4ug/mL methanol solution of cylinder was combined in a 1:1 ratio with a 10mg/mL ↵-
CHCA matrix and spotted onto steel plates. Peaks corresponding to [Ru2L3]
+, [Ru2L3]
2+ and
[Ru2L3]
3+ were observed but [Ru2L3]
4+ could not be seen. The most abundant peak occurred
at 1331.98 ([Ru2L3]
+) and so this was subjected to MS/MS analysis under standard instrument
conditions. However no fragmentation of this peak was achieved - only intact [Ru2L3]
+ as-
sociated peaks were observed in the MS/MS spectrum. This was not entirely unexpected as
the cylinder is a very stable structure, and the cylinder was already known to remain as an in-
tact molecule after ESI-MS analysis. However, without the ability to fragment the cylinder we
almost certainly would not be able to identify the cylinder in any tissue sample.
It was decided to repeat the experiment using 3 di↵erent matrices - DHB, SPA and THAP,
however all of these produced very poor results with very little ionisation of the cylinder ob-
served so it was decided to revert back to ↵-CHCA matrix. Work focused on optimising the
parameters of the collision induced dissociation stage to hopefully achieve fragmentation of
cylinder. By increasing the collision energy within the chamber during an MS/MS experiment
to the instrument’s maximum capability, peaks centred around m/z = 955.89 were observed
which corresponds to [Ru2L2]
2+ and which also showed the correct isotope pattern for this com-
pound. However the ion count for this species was less than 10, meaning it would be entirely
lost within the background of a tissue sample. There were also another set of peaks centred
at m/z = 1251.94 corresponding to another fragment of drug, as identified by its ruthenium
isotope pattern, but again the most abundant peaks were un-fragmented [Ru2L3]
+. Continued
alteration of instrument parameters ultimately showed that the peaks centred around m/z = 1251
correspond to the most abundant fragment, but again a maximum ion count of 10 was achieved
which is too low to be useful in any tissue experiment. MS/MS spectra of the [Ru2L3]
+ ion are
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shown in Figure 5.4(a) and 5.4(b).
Figure 5.4: Above, MS/MS spectra of [Ru2L3]
+ (m/z = 1331.0) ion produced
using ↵-CHCA matrix. Below, expansion of m/z = 1240 to 1260 showing the
correct isotope pattern for a dinuclear ruthenium compound.
Attention was therefore turned to using a technique which has recently been investigated
within our group - the doping of the matrix with metal ions not normally found within the
system [119]. The ionisation event within the instrument normally involves protonation of
the molecular ion when the sample is a relatively straight forward system of compound in
matrix spotted onto a steel plate. However, when the sample is a tissue-based system, the
ionisation event normally involves cationisation usually by sodium or potassium. The formation
of these metal-analyte adducts can massively complicate a spectrum; particularly if the analyte
can form adducts with both sodium and potassium. By doping the matrix with metals such
as lithium, caesium or silver, the sodium and potassium adducts are suppressed resulting in
much cleaner spectra due to only one major metal-analyte adduct being formed. As [Ru2L3]
4+
doesn’t fragment easily, using the doped matrix allows for the possibility of observing a metal-
cylinder adduct and attempting fragmentation of that; i.e. instead of looking for fragments of
the cylinder, look for the intact cylinder as a fragment of a larger adduct. With its distinctive
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isotope pattern, the cylinder should be relatively easy to identify provided it is seen in high
enough ion counts.
Lithium and silver chloride doped samples of ↵-CHCA were prepared, combined with cylin-
der and spotted onto steel plates. Analysis of silver doped samples revealed very little ionisation
of the cylinder - by far the most abundant peaks observed were silver adducts of ↵-CHCA. The
lithium doped samples were much more promising - whilst no lithium-cylinder adduct was ob-
served the mere presence of the lithium chloride was shown to increase ion counts of [Ru2L3]
+.
This leads to more ions entering the collision chamber, and so increased ion counts of all the
fragments - a maximum of 25 for m/z = 1251. Whilst this is still low, a two-fold increase in
ion count was observed with a first attempt at matrix doping. It is hoped that the ion count can
be improved further by optimising lithium concentration. MS/MS spectra of the [Ru2L3]
+ ion
recorded in lithium-doped matrix are shown in Figure 5.5(a) and 5.5(b).
Figure 5.5: Above, MS/MS spectra of [Ru2L3]
+ (m/z = 1331.0) ion produced
using lithium-doped ↵-CHCA matrix. Below, expansion of m/z = 1240 to 1260
showing the correct isotope pattern for a dinuclear ruthenium compound.
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Repetition of this experiment gave similar results, but it was qualitatively observed that the
spots of lithium-doped samples were much less uniform on the steel plates compared to non-
doped samples, and were more di cult to ablate. This very much represents ongoing work
to determine optimum lithium concentration and instrument parameters for fragmentation of
ruthenium cylinder, but it has been shown that the cylinder can be successfully ionised and
fragmented using MALDI mass spectrometry. To take this work forward, experiments on doped
tissue homogenates should be performed to determine the concentration of ruthenium needed
within a tissue to be observable above the background of the tissue spectrum.
MALDI mass spectrometry therefore o↵ers the opportunity to image and discover the
metabolic fate of cylinders within an animal, which is the next stage for the cylinders if they are
to become a genuine cancer therapeutic.
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Chapter 6
Experimental
6.1 Ligand synthesis
6.1.1 Synthesis of ligand L - C25H20N4
2-pyridine carboxaldehyde (1.4mL, 15.1mmol) and 4,4’-methylenedianiline (1.5g, 7.6mmol)
were combined in 100mL ethanol and left to stir at room temperature overnight. The
resulting pale yellow precipitate was filtered, washed with ethanol and dried in vacuo.
Yield = 2.09g (73%)
1H NMR (300MHz, CDCl3, 298K):   = 9.21 (2H, s, Him), 8.75 (2H, d, J=7.0Hz, H3), 8.51
(2H, d, J=4.2Hz, H6), 7.83 (2H, td, J=8.3, 1.9, 0.6Hz, H4), 7.39 (2H, ddd, J=7.6, 4.9, 1.2Hz,
H5), 7.29 (8H, m, Ha/b), 4.07(2H, s, HCH2).
ESI-MS: m/z = 775.7 [2L+Na]+
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6.1.2 Synthesis of ligand LMe - C27H24N4
The synthesis of LMe was first described in Ref [120], but is included here with this author’s
characterisation
4,4’-methylenedianiline (630mg, 3mmol) was added to 10g of 3A˙ dry molecular sieves in
100mL of toluene and left to stir until all 4,4’-methylenedianiline had dissolved.
2-acetylpyridine (0.71ml, 2mmol) was added and the solution was allowed to stir for three
days. The resulting mixture was filtered to remove molecular sieves and the filtrate reduced in
volume under vacuum to give a dark yellow oil.
Yield = 0.96g (74%)
1H NMR (300MHz, CDCl3, 298K):   = 8.70 (2H, d, J=4.0Hz, H6), 8.05 (2H, d, J=8.0Hz, H3),
7.98 (2H, td, J=7.5, 1.5Hz, H4), 7.45 (2H, dd, J=7.6, 1.2Hz, H5), 6.90 (4H, d, J=8.3Hz Ha/b),
6.70 (4H, d, J=8.3Hz Ha/b) 3.80 (2H, s, HCH2) 2.80 (6H, s, CH3).
ESI-MS: m/z = 405 [LMe+H]
6.1.3 Synthesis of ligand LO - C24H18N4O
The synthesis of LO was first described in Ref [95], but is included here with this author’s
characterisation.
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4,4’-diaminophenylether (1.00 g, 5 mmol) was dissolved in MeOH (10 mL) before a solution
of 2-pyridinecarboxaldehyde (1.2 g, 11 mmol) in MeOH (15 mL) was added and the mixture
was refluxed for 2 h. The solution was evaporated until precipitation occurred.
Yield: 1.10g (88%)
1H NMR (300 MHz, CDCl3, 298K):   = 8.70 (2H, d, J=5.0 Hz, H6), 8.65 (2H, s, Him), 8.20
(2H, d, J=8.1 Hz, H3), 7.80 (2H, t, J=7.9 Hz, H4), 7.35 (6H, m, H5, Ha/b), 7.10 (4H, d, J=8.7
Hz, Ha/b).
ESI-MS: m/z = 379 [L+H]
6.1.4 Synthesis of ligand LS - C24H18N4S
The synthesis of LS was first described in Ref [95], but is included here with this author’s
characterisation.
4,4’-thiodianiline (976.1mg g, 4.5 mmol) was dissolved in MeOH (10 mL) before a solution of
2-pyridinecarboxaldehyde (1.07 g, 10 mmol) in MeOH (5 mL) was added and the mixture was
refluxed for 2 h. The solution was cooled, filtered and evaporated until a dark yellow/green oil
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was obtained. Addition of dichloromethane gave a solid which was filtered and dried in vacuo.
Yield: 0.7191g (41%)
1H NMR (300 MHz, CDCl3, 298K):   = 8.60 (2H, d, J=4.5 Hz, H6), 8.45 (2H, s, Him), 8.05
(2H, d, J=8.0 Hz, H3), 7.68 (2H, t, J=6.3 Hz, H4), 7.25 (4H, m, Ha/b), 7.12 (6H, m, H5, Ha/b).
ESI-MS: m/z = 395 [L+H]
6.2 Fe-cylinder synthesis
6.2.1 Synthesis of [Fe2L3]Cl4
Ligand L (0.0301 g, 0.08 mmol) and iron(II) chloride (0.0106 g, 0.05 mmol) were heated
under reflux in MeOH (20mL) for 2 hr. The resulting purple-colored solution was cooled and
treated with saturated methanolic ammonium hexafluorophosphate. On cooling, a purple
precipitate ([Fe2L3](PF6)4) separated and was isolated by filtration (0.0408 g, 84%). Anion
exchange to [Fe2L3]Cl4 was carried out using tetrabutylammonium chloride.
1H NMR (300 MHz, MeOD, 298K):   = 9.20 (2H, s, Him), 8.75 (2H, d, J=7.0 Hz, H3), 8.50
(2H, t, J=6.5 Hz, H4), 7.90 (2H, t, J=6.0 Hz, H5), 7.50 (2H, d, J=4.0 Hz, H6), 7.10 (4H, s,
Ha/b), 5.60 (4H, s, Ha/b), 4.10 (2H, s, CH2).
ESI-MS: m/z 310 [Fe2L3]
4+
6.2.2 Synthesis of [Fe2L
Me
3]Cl4
The synthesis of [Fe2L
Me
3]Cl4 was first described in [120], but is included here with this
author’s characterisation. Ligand, LMe (205mg, 0.5mmol) was mixed with MeOH (50mL) and
stirred for 10min before the addition of FeCl2 · 4H2O (68mg, 0.3mmol) dissolved in MeOH
(50mL) giving a purple solution which was refluxed for three days. The reflux was allowed to
cool to room temperature before the addition of a saturated methanolic solution of NH4PF6
precipitated the desired product out of solution. The purple solid was filtered, washed with
MeOH and allowed to dry in vacuo. Yield = 0.192g (87%)
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Anion exchange to [Fe2L
Me
3]Cl4 was carried out using tetrabutylammonium chloride.
1H NMR (300 MHz, MeOD, 298K):   = 8.8 (2H, d, J=8.0Hz, H3), 8.8 (2H, t, J=7.5 Hz, H4),
7.80 (2H, t, J=6.5 Hz, H5), 7.50 (2H, dd, J=6.0 Hz, J=1.0Hz, Ha/b), 7.25 (2H, d, J=4.0 Hz, H6),
6.90 (2H, dd, J=6.5Hz, J=1.5Hz, Ha/b), 5.60 (2H, dd, J=8.5Hz, J=1.5Hz, Ha/b), 4.80(2H, dd,
J=8.5Hz, J= 1.5Hz, Ha/b, 4.65 (6H, s, CH3), 4.10 (2H, s, CH2).
raggedright ESI-MS: m/z = 395 [Fe2L
Me
3]
4+
6.2.3 Synthesis of [Fe2L
O
3]Cl4
This cylinder was synthesised under the same conditions as decribed in Section 6.2.1.
Yield = 0.452g (82%) 1H NMR (300 MHz, CD3CN, 298K):   = 9.20 (2H, s, Him), 8.65 (2H, d,
J=7.0 Hz, H3), 8.40 (2H, t, J=6.5 Hz, H4), 7.85 (2H, t, J=6.0 Hz, H5), 7.60 (2H, d, J=4.0 Hz,
H6), 6.50 (4H, bs, Ha/b), 5.80 (4H, bs, Ha/b).
ESI-MS: m/z = 312 [Fe2L
O
3]
4+
6.2.4 Synthesis of [Fe2L
S
3]Cl4
This cylinder was synthesised under the same conditions as decribed in Section 6.2.1.
Yield = 0.487g (86%)
1H NMR (300 MHz, CD3CN, 298K):   = 9.10 (2H, s, Him), 8.65 (2H, d, J=7.0 Hz, H3), 8.45
(2H, t, J=6.5 Hz, H4), 7.85 (2H, t, J=6.0 Hz, H5), 7.40 (2H, d, J=4.0 Hz, H6), 7.25 (4H, bs,
Ha/b), 5.55 (4H, bs, Ha/b).
ESI-MS: m/z = 324 [Fe2L
S
3]
4+
6.3 Ru-cylinder synthesis
6.3.1 Synthesis of cis-[Ru2(DMSO)4Cl2]
The synthesis of cis-[Ru2(DMSO)4Cl2] was first described in Ref [58], but is included here
with slight modification.
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cis-RuCl3 · 3H2O (1 g) was refluxed in DMSO (8 ml) for 5 min and allowed to cool. The
volume was reduced by half in vacuo and cold acetone (20 ml) was slowly added. After
refridgeration overnight, a yellow solid was filtered o↵, washed with acetone and ether, and
vacuum dried.
Yield = 1.33g (72%)
6.3.2 Synthesis of [Ru2L3]Cl4
Reflux synthesis
Ligand L (0.565g, 1.5mmol) and cis-[Ru(DMSO)4Cl2] (0.484g, 1mmol) were added to
ethylene glycol (20mL). The system was purged with nitrogen before being refluxed for 5 days
in an oil-bath preheated to 200 C. The initial yellow mixture became a dark-orange solution
upon completion of the reflux, which was then left to cool to room temperature, added to
100mL of saturated NH4PF6 aqueous solution and refrigerated overnight. The resulting dark
orange precipitate was filtered, washed with cold deionised water followed by diethyl ether
and left to dry in vacuo. This paste-like product was then re-precipitated from acetonitrile
using diethyl ether, and again refrigerated overnight. This precipitate was filtered, washed with
diethyl ether followed by chloroform and left to dry in vacuo.
The compound was purified by 3 successive silica gel columns using a 15mM NH4PF6 in
3:1 acetonitrile and water solution as the eluent. In all columns, the compound was eluted as
the first orange band, from which the solvent was removed and the compound re-precipitated
from acetonitrile using diethyl ether.
Yield = 3.2mg
1H NMR [Ru2L3](PF6)4 (300MHz, CD3CN, 25 C):   = 8.7 (s, 1H, Him), 8.5 (d, 1H, H3), 8.3
(td, 1H, H4) 7.7 (ddd, 1H, H5), 7.6 (d, 1H, H6), 7.0 (d, 2H, Ha/b) 5.7(d, 2H, Ha/b), 4.0 (s, 1H,
HCH2)
ESI-MS (CH3CN): m/z = 333.1 [Ru2L3]
4+ (100%), 444.1 [Ru2L3]
3+ (50%), 811.2
Ru2L3][PF6]2[Ru2L3][PF6]
2+
2 (15%)
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Microwave synthesis
Ligand L, (225.6mg, 0.6mmol) and RuCl3 · xH2O (82.8mg, 0.4mmol) were added to 20mL
ethylene glycol in a sealable microwave vial under a nitrogen atmosphere and heated at 200 C
for 4 hours. This resulted in a dark brown solution which was left to cool to room temperature,
added to 100mL of saturated NH4PF6 and refrigerated overnight. The cylinder was then
purified using the same procedure as used for the reflux synthesis described above.
Yield = 3.0mg (1%)
6.4 Cu-cylinder synthesis
6.4.1 Synthesis of [Cu2L3]Cl4
Ligand L, (301.9mg , 0.8mmol) and [Cu(MeCN)4][BF4] (251.8mg, 0.08mmol) were heated
under reflux at 75 C in 200mL methanol under a nitrogen atmosphere for 2hrs. The resulting
red solution was left to cool to room temperature, added to 100mL of saturated NH4PF6 and
refridgerated overnight. The dark red precipitate was filtered, washed with methanol and left to
dry in vacuo.
Yield = 419.1mg, 89.6%
6.4.2 Synthesis of copper-anthracene cylinder
The synthesis of anthracene-tagged ligand and the resulting cylinder were synthesised within
our lab by Nicholas J Hobson. The synthesis of the final cylinder and characterisation of the
final molecule is included for reference.
A solution of 5-(anthracen-2-ylcarbamoyl)picolinic acid (20 mg, 0.06 mmol) in MeOH (5 mL)
was purged with N2. 4,4-methylenedianiline ( 6 mg, 0.03 mmol) in MeOH (3 mL) was added,
followed by [Cu(CH3CN)4](BF4) (6.3 mg, 0.02 mmol) in MeOH (3 mL). The reaction was
stirred overnight under a N2 atmosphere to yield a red/brown precipitate which was isolated by
filtration and washed with methanol to yield the product in 55 mg (46 %) yield. ESI mass
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analysis: m/z = 878.3 [Cu2L
1
2]
2+, 893.0 [Cu2L
1
2]
2+(CH3OH), 908.3 [Cu2L
1
2]
2+(CH3OH)2.
6.5 Cell Culture Protocols
MDA-MB-231 cells were purchased from Sigma Aldrich and seeded in Dulbecco’s Modified
Eagles’ Medium (without phenol red) supplemented with 10% Foetal Bovine Serum (FBS)
and 1% Penicillin, L-glutamine and streptomycin. Cells were washed with phosphate bu↵ed
saline (PBS) and placed in fresh media every 2 days and cells were split when 80% confluence
was reached.
Prior to use, all coverslips were immersed in nitric acid for 10 minutes and then rinsed
thoroughly in deionised water. They were finally rinsed with ethanol and left to dry in an oven.
2mg [Ru2L3]
4+ was dissolved in 2mL media and kept as a stock solution at 4 C.
6.5.1 Treatment of cells with [Ru2L3]
4+
24 hours prior to treatment with [Ru2L3]
4+, 2.0 x105 cells were seeded on glass coverslips in
6-well plates with 2mL of media. Cells were then treated with the required volume of
[Ru2L3]
4+ in situ and incubated at 37 C for the required length of time. Each well was then
washed twice with PBS and 2mL of fresh media was added. Cells were then imaged live using
confocal microscopy.
6.5.2 Treatment of cells with Hoechst 34580 and [Ru2L3]
4+
24 hours prior to treatment, 2.0 x105 cells were seeded on glass coverslips in 6-well plates with
2mL of media. Cells were treated in situ with 0.4ug/mL Hoechst 34580 and incubated for 25
minutes at 37 C. Each well was washed with PBS and 2mL fresh media was added. Cells were
then treated with 15uM [Ru2L3]
4+ and incubated for 1.5 hours. Again each well was washed
twice with PBS and 2mL or fresh media was added. Cells were then imaged live using
confocal microscopy.
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6.5.3 Treatment of cells with Lifeact-GFP and [Ru2L3]
4+ or cytochalasin
D
24 hours prior to treatment, 1x105 cells were seeded on glass coverslips with 2mL of media in
6-well plates. Cells were treated with the DNA plasmid using TurboFect transfection reagent,
according to the manufacturer’s instructions, with slight modifications to published scale-up
ratios; well volume was kept at 2mL, and a TurboFect/DNA mixture was prepared to include
3ug of DNA with 300uL serum free media and 5uL of TurboFect for each well to be treated.
This was kept at room temperature for 20 minutes, and 300uL of the TurboFect/DNA mixture
was added to each well, and left to incubate at 37 C for 72 hours. Cells were then washed with
PBS, placed in 2mL fresh media and treated with the required concentration of [Ru2L3]
4+ or
cytochalasin D for the desired length of time. Cells were then fixed and imaged using confocal
microscopy.
6.5.4 ToxiLight BioAssay for detection of adenylate kinase (AK)
The ToxiLight BioAssay kit was purchased from Cambrex BioScience Ltd. 2x105 cells were
seeded in a 6-well plate with 2mL of media and incubated for 24 hours to allow for surface
attachment. Cells were treated with 12.5, 25, 50 or 100uM [Ru2L3]
4+. Control samples were
also prepared by treating cells with either Tris Acetate Bu↵er (negative control) or 100% Lysis
Reagent (positive control) in a 1:2 ratio of reagent to well volume. Both reagents were
supplied as part of the assay kit. Three samples of 30uL of supernatant were removed from
each well after 0, 2, 4 and 6 hours and frozen until required. Once all samples had been
gathered, 20uL of each collected supernatant was transferred to a 96-well plate suitable for use
with a luminescence microplate reader. 100uL of supplied AK detection reagent was added to
each well and left to equilibrate for 5 minutes. The intensity of the emitted light (340-700nm)
was then measured using a TECAN GENios Multifunction Microplate reader.
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6.5.5 MTT assay for determining cell viability
Based on the method first described in [121] 1x105 cells were seeded in a 96-well plate in
200uL of media and incubated for 24 hours to allow for surface attachment. Four wells were
treated with 100, 50, 25, 12.5 or 6.25uM of desired compound. Cisplatin was used as a control
on each plate tested. 72 hours after treatment, cells were washed twice with PBS and 200uL of
fresh media was added. 20uL of a 5mg/mL PBS solution of MTT was added to each well, and
left to incubate for 2 hours. After this, all media was removed and 200uL DMSO was added to
each well and left to incubate for a further 20 minutes. The absorbance of each well at 550nm
was then read. A dose-response curve was then plotted to determine the concentration of
compound at which only 50% of cells were viable.
6.6 Statistical Analysis
Initial analysis of data was performed by determining the mean and standard deviation of the
sample population, using the following formula;qP
(x x¯)2
n
Where x represents each data point, x¯ represents the mean of the population and n represents
the number of data points. Where appropriate, a Student’s t-test has been used to determine if
di↵erences in populations show significantly di↵erent results. Determination of the t-value was
performed using Excel function ’ttest’, and degrees of freedom were taken as number of
samples in each population less one. To determine if this result was significant, the calculated
t-value was compared to those included in t-tables as printed in [122]. A confidence interval of
p=0.05 and a two-tailed test were used to be confident that any significant di↵erence in either
direction was noted. Only if the calculated t-value was higher than that found within the
t-tables, was the result said to be significant.
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6.7 Imaging protocols
All confocal microscopy was performed using a Leica DM IRE2 system and visualised using
Leica confocal software. A 405nm diode laser was used to acquire DIC images and a 488nm
argon laser was used to acquire fluorescence images of [Ru2L3]
4+.
6.7.1 Live Cell Imaging
Coverslips were removed in turn from the 6-well plate and placed in an Attofluor cell chamber,
purchased from Invitrogen. 1mL of media was added and a second coverslip was used to seal
the chamber. To maintain cell integrity, a heated stage was used to keep the cells at 37 C
during image acquisition.
6.7.2 Fixed Cell Imaging
Cells were fixed in 4% paraformaldehyde using the following protocol. 4g paraformaldehyde
was dissolved in 100mL PBS and pH adjusted to 7.4 using hydrochloric acid and sodium
hydroxide. Media was removed from the cells which were washed with PBS. 1mL of
paraformaldehyde was added and the cells were left in the dark at room temperature for 20
minutes. The paraformaldehyde was removed and each well was washed 3 times with PBS. A
small amount of Vectamount (a commercially available fixing agent) was placed on a
microscope slide and the coverslip was lifted out of the media and placed cell side down onto
the Vectamount. This was left to dry for 2 hours and the coverslip edges were sealed onto the
microscope slide with a coat of nail varnish. Slides were then kept in the dark at 4 C until
imaged.
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6.8 Synchrotron Imaging
6.8.1 Quartz slide sample preparation
75x25mm quartz slides (UQG Optics Ltd, UK - Part no. FQM-7521) were washed with
ethanol and a Flexiperm silicon ring cell culture chamber attached to each slide. 2mL of FBS
was added to the growth chamber for 30 minutes to aid cell attachment. After removing the
FBS, 200,000 cells in 2mL media were added to each growth chamber. Slides were stored in
petri dishes and incubated at 37 C in 5% CO2 for 24hrs. Cells were then treated with
compound at the required concentration and time. Cells were then washed with PBS and fixed
by plunge freezing in dry-ice cooled methanol. Cells were stored at -20 C until required for
imaging.
6.8.2 SiN3 window sample preparation
5x5mm silicon nitride windows with membrane thickness 200nm (Silson Ltd, UK. Ref
10610106) were washed by dipping in ethanol, followed by PBS and then media before being
placed in individual wells of a 6-well plate. To ensure cells attached predominantly to the
window, a concentrated stock of 2x105 cells in 1mL of media was prepared. 80uL of this stock
(⇡16,000 cells) was added directly on top of each window and left to begin to adhere for
45mins. 2mL of fresh media was added to each well and cells were incubated for 24hrs. Cells
were treated with compound and frozen in the same way as described in 6.8.1.
6.8.3 Synchrotron imaging and XANES spectroscopy
Once mounted onto the I18 beamline, samples were optically imaged to use a reference for
elemental distribution maps. A helium cryojet was used to protect the cells from radiation
damage. A four element Vortex detector was used in rastering mode to measure X-ray
fluorescence. A beam of approximately 5x5 microns was used to map areas of ⇡200x200um2
to allow for imaging of a number of cells in each imaging run. A beam energy of 11keV was
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used to map the metals of interest (Fe and Ni) whilst also detecting cellular elements such as
Cl, Ca and Zn. Where areas of high metal concentration were found, XANES spectra were
recorded using beam energy appropriate for the K-edge of each metal - 7112keV for Fe and
8333keV for Ni. XANES spectra of pellets of cylinder powder were also recorded for
reference. Reference spectra of Fe foil and ferrihydrite were provided by Dr Tina Geraki of
Diamond. Elemental maps were generated constructed using PyMCA software [123] by
normalising the fluorescence signals with the incoming X-ray beam intensity, I0. Signal peaks
due to detector glitches were removed by applying an upper limit on normalised intensity at
the 99th percentile. XANES spectra were analysed using Athena software (IFFEIT) [92],
protocols for background subtraction were provided by Dr Tina Geraki [88]. The pre-edge
background was removed by a linear approximation in the range of 30 to 150 eV for iron (or
-13 to -21 eV for nickel) before the edge and subtraction of this baseline from the overall data.
The spectra was then normalised by fitting a quadratic polynomial to the post-edge region of
the spectra from 48 to 97 eV when looking at iron data, or 44 to 85 eV when looking at nickel.
The edge position of the element was identified as the maximum in the first derivative of the
spectrum, which correlated to the inflection point of the steeply rising edge. Linear
combination analysis was performed followed protocols as provided within Athena manuals,
with spectra of all standards available included within the population used by Athena to
determine fitting.
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Chapter 7
Conclusions and Future Work
Three key aspects of work regarding the cylinders has been addressed in this work - the
synthesis of a ruthenium based cylinder, determining the cellular localisation of the cylinders
also determining the cellular e↵ects of the cylinders.
The first issued considered was to improve the synthetic protocol of the ruthenium cylinder.
This is the most challenging of the cylinders to make, due to the non-reactive nature of the
starting materials and the formation of polymeric side products. Within the literature, there is
only one other example of a ruthenium triple helicate compound [64], and it was this paper
that was used as a starting point for developing a microwave synthesis protocol. The 36 %
yield achieved by Glasson et al. could not be repeated with the ruthenium cylinder, which was
surprising given the similarity between the two compounds. It was however noted as part of
this work, that the syntheses that gave the greatest yields were those where no pressure built up
within the microwave system. This has led to the conclusion that there is a contaminant within
some of the attempted syntheses that has a higher vapour pressure than the intended
components, leading to incomplete reactions within the microwave. This therefore leads to a
suggestion for future work to be to consider further which solvents are suitable for use within a
microwave, and then favour those which are available as dry solvents so hopefully removing
any contaminants. The purification of the ruthenium cylinder has historically also been
problematic, with both large amounts of material adhering to the solid phase of any column
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chromatograph and also the cylinder elutes very closely to other by-products. This continues
to remain an issue, however the use of Sephadex as a solid phase (as opposed to silica or
alumina) has led to a more e cient purification, as now only two columns are typically
required to obtain pure ruthenium cylinder as opposed to the three or four used previously. An
increased yield in percentage terms is now reported, with a shorter synthetic protocol which
now no longer required the synthesis of an intermediary compound, Ru(DMSO)4Cl2. This
therefore represents a positive step forward for the synthesis of this compound. However, this
work may still be able to be improved upon by surveying a family of Ru(II) compounds as it is
hypothesised that starting with a metal of the required oxidation state would lead to a higher
yield. As discussed earlier in this work the fluorescent properties of the ruthenium cylinder
mean that improving the synthesis of this compound is something that is worthwhile, to allow
for further investigation into the cellular localisation of this class of compounds.
As the synthesis of the ruthenium cylinder continued to be time-consuming, an alternative
strategy of imaging a cylinder which has been modified to contain a fluorescent moiety has
also been investigated. A modified copper based cylinder which contains an anthracene group
attached to the end of each ligand has been prepared within the research group [73], but has
been considered as part of this work as its suitability as an imaging probe. The use of an
integrated UV-Vis spectrometer has shown that the anthracene moiety remains bound to parent
ligand within MDA-MB-231 cells, but as no fluorescence due to a metal-ligand transition is
observed, it cannot be said if the cylinder structure is stable as a whole. The addition of the
anthracene moiety vastly increases the size of each ligand, making it di cult to form a triple
stranded cylinder. Whilst the double stranded cylinders have previously been synthesised
[124], they have not previously been used within cellular studies. The related compound
[Cu2L2]
2+ has been shown to be stable in solution following stability studies performed using
absorption spectroscopy, and so this does present a potential future line of work. However by
altering the cylinder structure, none of the data previously gathered in relation to the triple
stranded cylinder can be relied upon to be relevant for this compound. This is especially true
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given that it has already been found that the reduced charge on a copper double-stranded
cylinder is responsible for reduced DNA binding in solution when compared to iron cylinder
[124]. It is therefore proposed that any future work performed utilising a fluorophore tagged
cylinder is part of development of that compound in its own right - although di cult to
produce, to use fluorescence microscopy to view the localisation of the cylinders needs to be
performed utilising an inherent property of the cylinders, only then can any results found from
imaging studies be truly correlated to any cell assays or DNA binding studies already
performed.
A first attempt at determination of the cellular localisation of the cylinders has been
undertaken, with initial confocal microscopy showing observable fluorescence from the
ruthenium cylinder within MDA-MB-231 cells, but not within SKOV-3 cells. This result
opened a series of questions, such as is the lack of fluorescent signal due to preferential uptake
of the ruthenium cylinder in MDA-MB-231 compared to SKOV-3 cells, or is it due to the
ruthenium cylinder being metabolised within the SKOV-3 cells (and so losing the Ru-N6
chromophore) but remaining intact within MDA-MB-231 cells? MTT data presented here has
shown that free ruthenium is not toxic to SKOV-3 cells and it has previously been shown that
the free ligand is also not toxic to this cell line [42]. The iron analogue of the cylinder has been
shown to be toxic to SKOV-3 cells [41], so there is no reason to believe that the ruthenium
cylinder would not be taken into the SKOV-3 cells, however there is no conclusive evidence to
say that the cylinder has in fact entered the cell. It therefore remains unclear as to why no
fluorescence is observed within these samples. It does however show a degree of selectivity in
the uptake or metabolism of this compound in these two cell lines. As one of the main
drawbacks of initial anti-cancer metallo-drugs was a lack of selectivity between cell types, this
result does add to cell test data showing that not all cell lines are a↵ected by the cylinders [14],
further enhancing the potential for this class of compounds to be considered for use in clinical
applications.
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An initial ’proof of concept’ experiment has shown that it is possible to perform
co-localisation experiments with Hoechst nuclear stains, which appear to show a reduction in
mean fluorescence in MDA-MB-231 cells which have been labelled with Hoechst, following
further treatment with iron cylinder. This suggests that the cylinder is either quenching
Hoechst emission, or is displacing it from binding to DNA. The initial result presented here
has since been supported by further research within the group that showed over a Z-stack of
images capturing entire cells, mean Hoechst fluorescence decreased following treatment with
the iron cylinder [76]. These results combined show that at least some of the cylinder that
enters the cells is localised within the nucleus of MDA-MB-231 cells. This is a significant
result as it means that the DNA-binding studies performed in solution, particularly those that
show prevention of DNA replication [44], may be replicated within a cellular environment.
But it is synchrotron radiation that seemingly o↵ers the most promising route to
investigating cylinder localisation within cells. This is due to the compound being able to be
imaged without requiring any properties such as fluorescence, or modification to achieve
fluorescence. It also allows for the imaging of multiple cylinders in multiple cell lines under
comparable conditions, and as such, this represents the main focus of future work. A sample
preparation route of growing cells on silicon nitride windows has been developed, and allowed
for the imaging of iron and nickel cylinders within SKOV-3 cells. This showed that high levels
of iron are found near the cell membrane, corresponding to areas of high calcium
concentration, whereas nickel is found more uniformly spread throughout the cell. However,
as both nickel and iron are endogenous elements, the aim continues to be to use this technique
to image ruthenium within cells, as all ruthenium observed can then only be attributable to
treatment with the cylinder. This however is not possible using the I-18 beamline at Diamond
Light Source. The K-edge of Ru is around 22keV which is above the 20.5keV upper energy
limit of I-18. The L-lines of Ru (L↵=2.56keV and L =2.68keV) are within the energy range
of I-18 but they coincide with the K-lines of Cl (K↵=2.62keV and K =2.82keV) and, given
the abundance of Cl within the cells, the would make distinguishing the two elements very
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di cult. Any further work in this respect would have to be performed at another facility such
as Advanced Photon Source, Chicago. However, the imaging of iron has led to the observation
of ’hot spots’ near the cell membrane. Linear combination analysis of XANES spectra
(including standards of ferrihydrite and powdered cyliner) of these areas show that the iron
found there is a mixture of Fe(III) and Fe(II). This finding of an environment of mixed Fe
oxidation states does however support a hypothesis that the iron cylinder may be taken into
cells using the transferrin pathway. This represents the first time that any chemical information
about the cylinder has been obtained within a biological system, and so again opens up new
avenues of further investigation such as potential co-localisation studies between cells
containing fluorescently tagged transferrin receptors and the cylinders.
As well as attempting to determine the localisation of the cylinder, the cellular e↵ects of
cylinder treatment upon two cell lines have also been imaged by producing phase contrast
videos. The striking observation from these videos being that the motility of cells is
compromised by cylinder treatment. While this e↵ect has not been quantified, the consistency
with which this observation was noted lead to cause of the arrest to be investigated. As a
polymer that is well known to be involved in cell motility [96], the e↵ect of the cylinders upon
the cellular actin structure has been investigated. Given the filamentous nature of actin
structure, it was hypothesised that the cylinder would be able to bind to the junctions of actin
fibres, much in the same way it binds to Y-shaped junctions of DNA. The actin structure of
MDA-MB-231 cells was shown to be disrupted following cylinder treatment, but it is now
understood that this is not due to direct binding of the cylinder to actin - fluorescence
co-localisation studies led to very little overlap being observed between the two. When the
structures of compounds which are know to bind to actin such as phalloidin, cytochalasin D
and Lifeact (all of which are significantly larger, more flexible molecules) are considered, it is
perhaps unsurprising that the cylinder does not specifically bind to actin. A literature review of
factors a↵ecting the motility of the MDA-MB-231 cell line led to research being uncovered
which debated the impact of NO upon this cell line, and indeed a debate on whether these cells
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produce endogenous NO [104], [106], [107] and [108]. Using a newly developed NO cellular
probe, NO550, the production of NO within MDA-MB-231 cells was observed following
treatment with both iron cylinder and ruthenium nitrosyl, which was used as a positive control.
Very low levels of fluorescence were observed within the control sample, which adds evidence
to the literature debate that these cells do indeed contain endogenous NO. The observation of
increased NO within the cells following treatment with iron cylinder is a significant
advancement in the understanding of the mode of action of these compounds. Whilst it was
known that the ruthenium cylinder can lead to the production of singlet oxygen within a cell
[3], this was only observed following UV irradiation - this is the first time the cylinders have
been seen to lead to the production of a gaseous species within a cell. Future work in this
respect must therefore concentrate on repeating this experiment in multiple cell lines, with
multiple cylinders and at multiple time points to determine if it is the level of production of
NO within cells that is determining the overall toxicity of the cylinders.
This work represents the first attempt at using imaging techniques to determine the
localisation and e↵ect of a class of novel cancer therapeutics on a range on cancer cell lines.
Whilst progress has been made to answer these questions, there any now many more avenues
of work which can be pursued to discover the full range of e↵ects the cylinders have upon a
cell, and so establish if this class of compounds can be considered a truly promising cancer
therapeutic.
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Chapter 9
Publications Arising
Work contained within this thesis has been presented as posters at two conferences, the
abstracts of which are included here.
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Figure 9.1: Abstract submitted to Diamond Synchrotron Users Meeting,
September 2012
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